

# Wiesje M Van Der Flier

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1804743/publications.pdf>

Version: 2024-02-01

846  
papers

46,559  
citations

1704

104  
h-index

3732

179  
g-index

970  
all docs

970  
docs citations

970  
times ranked

32872  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nutritional Status Is Associated With Clinical Progression in Alzheimer's Disease: The NUDAD Project. Journal of the American Medical Directors Association, 2023, 24, 638-644.e1.	2.5	10
2	Identifying best practices for disclosure of amyloid imaging results: A randomized controlled trial. Alzheimer's and Dementia, 2023, 19, 285-295.	0.8	12
3	Global estimates on the number of persons across the Alzheimer's disease continuum. Alzheimer's and Dementia, 2023, 19, 658-670.	0.8	146
4	The natural history of primary progressive aphasia: beyond aphasia. Journal of Neurology, 2022, 269, 1375-1385.	3.6	23
5	Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurology, The, 2022, 21, 66-77.	10.2	360
6	Psychosocial Effects of COVID-19 Measures on (Pre-)Dementia Patients During Second Lockdown. Journal of Alzheimer's Disease, 2022, 86, 931-939.	2.6	7
7	Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1951-1963.	6.4	8
8	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	9.0	97
9	Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies. Neurology, 2022, 98, .	1.1	10
10	Neuropsychiatric Symptoms as Predictor of Poor Clinical Outcome in Patients With Vascular Cognitive Impairment. American Journal of Geriatric Psychiatry, 2022, , .	1.2	1
11	Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping. Alzheimer's Research and Therapy, 2022, 14, 22.	6.2	5
12	Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline. Neurology, 2022, 98, .	1.1	41
13	Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review. Alzheimer's Research and Therapy, 2022, 14, 31.	6.2	25
14	Grey matter network markers identify individuals with prodromal Alzheimer's disease who will show rapid clinical decline. Brain Communications, 2022, 4, fca026.	3.3	4
15	Decreased integrity of the monoaminergic tract is associated with a positive response to MPH in patients with vascular cognitive impairment - proof of principle study STREAM-VCI. Cerebral Circulation - Cognition and Behavior, 2022, 3, 100128.	0.9	0
16	Spatial-Temporal Patterns of $\beta^2$ -Amyloid Accumulation. Neurology, 2022, 98, .	1.1	40
17	Association of Education and Intracranial Volume With Cognitive Trajectories and Mortality Rates Across the Alzheimer Disease Continuum. Neurology, 2022, 98, .	1.1	17
18	A comparison of two approaches for modeling dementia progression in a changing patient context. International Journal of Geriatric Psychiatry, 2022, 37, .	2.7	3

#	ARTICLE	IF	CITATIONS
19	Cerebrovascular disease in suspected non-Alzheimer's pathophysiology and cognitive decline over time. <i>European Journal of Neurology</i> , 2022, 29, 1922-1929.	3.3	4
20	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	21.4	700
21	The protective gene dose effect of the <i>APOE</i> $\epsilon 2$ allele on gray matter volume in cognitively unimpaired individuals. <i>Alzheimer's and Dementia</i> , 2022, 18, 1383-1395.	0.8	13
22	Characteristics of subjective cognitive decline associated with amyloid positivity. <i>Alzheimer's and Dementia</i> , 2022, 18, 1832-1845.	0.8	22
23	Pre-Diagnostic Symptoms of Young-Onset Dementia in the General Practice up to Five Years Before Diagnosis. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 229-239.	2.6	6
24	Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	2.4	28
25	Subjective cognitive decline and self-reported sleep problems: The SCIENCE project. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	2.4	5
26	Association of Rare <i>APOE</i> Missense Variants V236E and R251G With Risk of Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 652.	9.0	31
27	Clinical applicability of quantitative atrophy measures on MRI in patients suspected of Alzheimer's disease. <i>European Radiology</i> , 2022, 32, 7789-7799.	4.5	3
28	Does Loss of Integrity of the Cingulum Bundle Link Amyloid- $\beta$ Accumulation and Neurodegeneration in Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2022, 89, 39-49.	2.6	2
29	Repeatability of parametric methods for [ <sup>18</sup> F]florbetapir imaging in Alzheimer's disease and healthy controls: A test-retest study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 569-578.	4.3	10
30	Dietary patterns are related to cognitive functioning in elderly enriched with individuals at increased risk for Alzheimer's disease. <i>European Journal of Nutrition</i> , 2021, 60, 849-860.	3.9	31
31	Hypertensive Exposure Markers by MRI in Relation to Cerebral Small Vessel Disease and Cognitive Impairment. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 176-185.	5.3	18
32	Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 426-438.	1.8	30
33	Circulating metabolites are associated with brain atrophy and white matter hyperintensities. <i>Alzheimer's and Dementia</i> , 2021, 17, 205-214.	0.8	17
34	Classification of negative and positive 18F-florbetapir brain PET studies in subjective cognitive decline patients using a convolutional neural network. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 721-728.	6.4	16
35	Grey zone amyloid burden affects memory function: the SCIENCE project. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 747-756.	6.4	5
36	Risk of dementia in <i>APOE</i> $\epsilon 4$ carriers is mitigated by a polygenic risk score. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12229.	2.4	16

#	ARTICLE	IF	CITATIONS
37	Cross-cohort generalizability of deep and conventional machine learning for MRI-based diagnosis and prediction of Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2021, 31, 102712.	2.7	42
38	Effect of Shortening the Scan Duration on Quantitative Accuracy of [18F]Flortaucipir Studies. <i>Molecular Imaging and Biology</i> , 2021, 23, 604-613.	2.6	10
39	Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer's disease subgroups. <i>NeuroImage: Clinical</i> , 2021, 30, 102660.	2.7	13
40	Biomarker testing in MCI patients—deciding who to test. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 14.	6.2	6
41	Four subgroups based on tau levels in Alzheimer's disease observed in two independent cohorts. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 2.	6.2	18
42	Amyloid- $\beta$ , cortical thickness, and subsequent cognitive decline in cognitively normal oldest-old. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 348-358.	3.7	9
43	Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [18F]Flortaucipir and [18F]Florbetapir Brain PET Studies. <i>Molecular Imaging and Biology</i> , 2021, 23, 550-559.	2.6	2
44	Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline results. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 53.	6.2	21
45	The Right Temporal Variant of Frontotemporal Dementia Is Not Genetically Sporadic: A Case Series. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1195-1201.	2.6	10
46	Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. <i>The Lancet Healthy Longevity</i> , 2021, 2, e87-e95.	4.6	85
47	Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2157-2168.	6.4	18
48	Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, 1189-1204.	0.8	44
49	Alzheimer's disease. <i>Lancet</i> , The, 2021, 397, 1577-1590.	13.7	1,530
50	Contribution of Gut Microbiota to Immunological Changes in Alzheimer's Disease. <i>Frontiers in Immunology</i> , 2021, 12, 683068.	4.8	25
51	Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity. <i>Neurology</i> , 2021, 96, e2673-e2684.	1.1	37
52	Clinical Phenotypes of Behavioral Variant Frontotemporal Dementia by Age at Onset. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 381-390.	2.6	8
53	Highly specific and ultrasensitive plasma test detects A $\beta$ (1-42) and A $\beta$ (1-40) in Alzheimer's disease. <i>Scientific Reports</i> , 2021, 11, 9736.	3.3	49
54	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	12.8	140

#	ARTICLE	IF	CITATIONS
55	Assessing the Views of Professionals, Patients, and Care Partners Concerning the Use of Computer Tools in Memory Clinics: International Survey Study. <i>JMIR Formative Research</i> , 2021, 5, e31053.	1.4	6
56	Diagnostic Value of the CSF $\pm$ -Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies. <i>Neurology</i> , 2021, 97, e930-e940.	1.1	51
57	Plasma amyloid- $\beta$ oligomerization assay as a pre-screening test for amyloid status. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 133.	6.2	19
58	Measuring Resilience and Resistance in Aging and Alzheimer Disease Using Residual Methods. <i>Neurology</i> , 2021, 97, 474-488.	1.1	46
59	[ <sup>18</sup> F]Flortaucipir PET Across Various $\tau$ MAPT Mutations in Presymptomatic and Symptomatic Carriers. <i>Neurology</i> , 2021, 97, e1017-e1030.	1.1	16
60	Genetics Contributes to Concomitant Pathology and Clinical Presentation in Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 269-279.	2.6	10
61	Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum. <i>Neurology</i> , 2021, 97, e1276-e1287.	1.1	44
62	Sex and Cardiovascular Function in Relation to Vascular Brain Injury in Patients with Cognitive Complaints. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 261-271.	2.6	2
63	Comparing a Single Clinician Versus a Multidisciplinary Consensus Conference Approach for Dementia Diagnostics. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 741-751.	2.6	2
64	Global Prevalence of Young-Onset Dementia. <i>JAMA Neurology</i> , 2021, 78, 1080.	9.0	124
65	A Cystatin C Cleavage ELISA Assay as a Quality Control Tool for Determining Sub-Optimal Storage Conditions of Cerebrospinal Fluid Samples in Alzheimer's Disease Research. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1367-1377.	2.6	0
66	Genome-wide association study of frontotemporal dementia identifies a C9ORF72 haplotype with a median of 12-G4C2 repeats that predisposes to pathological repeat expansions. <i>Translational Psychiatry</i> , 2021, 11, 451.	4.8	6
67	Serum and cerebrospinal fluid Neutrophil gelatinase-associated lipocalin (NGAL) levels as biomarkers for the conversion from mild cognitive impairment to Alzheimer's disease dementia. <i>Neurobiology of Aging</i> , 2021, 107, 1-10.	3.1	12
68	BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: the SCIENCE project. <i>Neurobiology of Aging</i> , 2021, 108, 146-154.	3.1	6
69	Identifying relevant outcomes in the progression of Alzheimer's disease; what do patients and care partners want to know about prognosis?. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12189.	3.7	15
70	Differential trajectories of hypometabolism across cognitively-defined Alzheimer's disease subgroups. <i>NeuroImage: Clinical</i> , 2021, 31, 102725.	2.7	9
71	The Cognitive Online Self-Test Amsterdam (COST): Establishing norm scores in a community-dwelling population. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12234.	2.4	3
72	Polygenic Risk Score of Longevity Predicts Longer Survival Across an Age Continuum. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 750-759.	3.6	20

#	ARTICLE	IF	CITATIONS
73	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Servicesâ€”part 2 of 6. Alzheimer's Research and Therapy, 2021, 13, 169.	6.2	35
74	Dementia risk communication. A user manual for Brain Health Servicesâ€”part 3 of 6. Alzheimer's Research and Therapy, 2021, 13, 170.	6.2	21
75	Short Digital Spatial Memory Test Detects Impairment in Alzheimerâ€™s Disease and Mild Cognitive Impairment. Brain Sciences, 2021, 11, 1350.	2.3	6
76	Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Servicesâ€”part 1 of 6. Alzheimer's Research and Therapy, 2021, 13, 168.	6.2	26
77	Everyday Functioning in a Community-Based Volunteer Population: Differences Between Participant- and Study Partner-Report. Frontiers in Aging Neuroscience, 2021, 13, 761932.	3.4	4
78	Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimer's Research and Therapy, 2021, 13, 198.	6.2	87
79	Clinical and analytical comparison of three assays for plasma p-tau isoforms on an ultrasensitive platform. Alzheimer's and Dementia, 2021, 17, .	0.8	0
80	Psychosocial effects of Corona virus measures on (pre-)dementia patients during 2 <sup>nd</sup> lockdown. Alzheimer's and Dementia, 2021, 17, e053995.	0.8	0
81	Can we improve clinical trial design in Alzheimerâ€™s disease? The participants point of view. Alzheimer's and Dementia, 2021, 17, .	0.8	0
82	Measuring synaptic loss in early AD stages: Trajectories of SNAP25 and SYT1 using serial CSF sampling. Alzheimer's and Dementia, 2021, 17, .	0.8	0
83	At-home assessment of cognitive performance: Establishing norm scores for the Cognitive Online Self-Test Amsterdam (COSTA). Alzheimer's and Dementia, 2021, 17, .	0.8	1
84	A stepwise approach towards diagnostic workup in dementia using online cognitive tools. Alzheimer's and Dementia, 2021, 17, .	0.8	0
85	ATN classification in dementia with Lewy bodies: Association with clinical profile, cognitive decline and survival. Alzheimer's and Dementia, 2021, 17, .	0.8	1
86	Mapping associations across multiple aspects of Alzheimer disease and the role of CSF biomarkers in individuals without dementia. Alzheimer's and Dementia, 2021, 17, .	0.8	0
87	Longitudinal [ <sup>18</sup> F]flortaucipir PET: Comparison of quantitative and semi-quantitative parameters. Alzheimer's and Dementia, 2021, 17, .	0.8	0
88	Everyday functioning in a community-based volunteer population: Factors associated with concordance between participant and study partnerâ€™ Report. Alzheimer's and Dementia, 2021, 17, .	0.8	0
89	The (non)sense of diagnostic computer tools in memory clinics: An international survey assessing the views of clinicians, patients and caregivers. Alzheimer's and Dementia, 2021, 17, .	0.8	1
90	Identifying and characterizing patterns of functional decline in memory clinic patients. Alzheimer's and Dementia, 2021, 17, .	0.8	0

#	ARTICLE	IF	CITATIONS
91	Residual approaches to capture resilience and resistance in aging and Alzheimer's disease: A meta-analysis. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
92	Novel CSF inflammatory markers MIF and TREM-1 are increased in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
93	An accurate diagnosis contributes to delayed institutionalization and mortality: The ABIDE Project. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
94	Subjective cognitive decline and self-reported sleep at a memory clinic: The SCIENCE project. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
95	Data-driven evidence for three distinct patterns of amyloid $\beta$ accumulation. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	2
96	The incidence of young onset dementia: A systematic review and meta-analysis. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
97	Cognitive decline in possible vascular cognitive impairment (VCI): Does the form of vascular brain injury matter?. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
98	The Effect of Alzheimer's Disease-Associated Genetic Variants on Longevity. <i>Frontiers in Genetics</i> , 2021, 12, 748781.	2.3	7
99	Predicting institutionalization and mortality across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
100	Study design of FINGER: A multidomain lifestyle intervention in Dutch older adults to prevent cognitive decline. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	2
101	CSF protein panels reflecting multiple pathophysiological mechanisms for early and specific diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
102	Young-onset dementia in memory clinics in the Netherlands: PRECODE-GP. <i>Alzheimer's and Dementia</i> , 2021, 17, e053524.	0.8	0
103	The majority of the patients with a monogenic predisposition for dementia did not fulfill current criteria for genetic testing.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e052075.	0.8	0
104	Test-retest repeatability of [ <sup>18</sup> F]Flortaucipir PET in Alzheimer's disease and cognitively normal individuals. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 2464-2474.	4.3	23
105	Olfactory and gustatory functioning and food preferences of patients with Alzheimer's disease and mild cognitive impairment compared to controls: the NUDAD project. <i>Journal of Neurology</i> , 2020, 267, 144-152.	3.6	21
106	Reply to "Usefulness of Plasma Amyloid as Prescreener of the Earliest Alzheimer Pathological Changes Depends on the Study Population". <i>Annals of Neurology</i> , 2020, 87, 155-155.	5.3	3
107	Communicating uncertainties when disclosing diagnostic test results for (Alzheimer's) dementia in the memory clinic: The ABIDE project. <i>Health Expectations</i> , 2020, 23, 52-62.	2.6	20
108	Methylphenidate and galantamine in patients with vascular cognitive impairment—the proof-of-principle study STREAM-VCI. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 10.	6.2	10

#	ARTICLE	IF	CITATIONS
109	Hippocampal [18F]flortaucipir BPND corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships. <i>NeuroImage: Clinical</i> , 2020, 25, 102113.	2.7	5
110	Why Is Amyloid- $\beta$ PET Requested After Performing CSF Biomarkers?. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 559-569.	2.6	8
111	Comorbid amyloid- $\beta$ pathology affects clinical and imaging features in VCD. <i>Alzheimer's and Dementia</i> , 2020, 16, 354-364.	0.8	6
112	Brain amyloid $\beta$ , cerebral small vessel disease, and cognition. <i>Neurology</i> , 2020, 95, e2845-e2853.	1.1	30
113	Immune response and endocytosis pathways are associated with the resilience against Alzheimer's disease. <i>Translational Psychiatry</i> , 2020, 10, 332.	4.8	33
114	Profound regional spectral, connectivity, and network changes reflect visual deficits in posterior cortical atrophy: an EEG study. <i>Neurobiology of Aging</i> , 2020, 96, 1-11.	3.1	7
115	Energy intake and expenditure in patients with Alzheimer's disease and mild cognitive impairment: the NUDAD project. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 116.	6.2	18
116	Identifying a task-invariant cognitive reserve network using task potency. <i>NeuroImage</i> , 2020, 210, 116593.	4.2	12
117	Multitracer model for staging cortical amyloid deposition using PET imaging. <i>Neurology</i> , 2020, 95, e1538-e1553.	1.1	55
118	Latent atrophy factors related to phenotypical variants of posterior cortical atrophy. <i>Neurology</i> , 2020, 95, e1672-e1685.	1.1	19
119	Psychosocial Effects of Corona Measures on Patients With Dementia, Mild Cognitive Impairment and Subjective Cognitive Decline. <i>Frontiers in Psychiatry</i> , 2020, 11, 585686.	2.6	52
120	Small vessel disease lesion type and brain atrophy: The role of co-occurring amyloid. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12060.	2.4	7
121	Prediction of poor clinical outcome in vascular cognitive impairment: TRACE-VCI study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12077.	2.4	5
122	cCOG: A web-based cognitive test tool for detecting neurodegenerative disorders. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12083.	2.4	9
123	Cerebral blood flow and cognitive functioning in patients with disorders along the heart-brain axis. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12034.	3.7	15
124	Sex differences in CSF biomarkers vary by Alzheimer disease stage and <i>APOE</i> $\epsilon$ 4 genotype. <i>Neurology</i> , 2020, 95, e2378-e2388.	1.1	48
125	Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson's Disease Patients and Is Present within Lewy Bodies. <i>Biomolecules</i> , 2020, 10, 1177.	4.0	14
126	Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies. <i>Alzheimer's and Dementia</i> , 2020, 16, 1457-1468.	0.8	43

#	ARTICLE	IF	CITATIONS
127	Nutritional status and structural brain changes in Alzheimer's disease: The NUDAD project. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12063.	2.4	9
128	A clinical-radiological framework of the right temporal variant of frontotemporal dementia. Brain, 2020, 143, 2831-2843.	7.6	76
129	Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study. NeuroImage: Clinical, 2020, 28, 102504.	2.7	14
130	Improving patient care through a national memory clinic network. Alzheimer's and Dementia, 2020, 16, e039017.	0.8	0
131	Gait disturbances are associated with increased CSF tau levels in a memory clinic cohort. Alzheimer's and Dementia, 2020, 16, e040152.	0.8	0
132	Determinants of cognitive decline and dementia in stage 2: The SCIENCE project. Alzheimer's and Dementia, 2020, 16, e040263.	0.8	0
133	Functional interpretation of genetic risk loci for dementia using a protein quantitative trait loci (pQTLs) approach in cerebrospinal fluid. Alzheimer's and Dementia, 2020, 16, e040774.	0.8	0
134	Amyloid $\beta$ deposition in cognitively normal oldest-old is associated with cortical thinning and faster memory decline. Alzheimer's and Dementia, 2020, 16, e040991.	0.8	0
135	Tau pathology, relative cerebral flow and cognition in dementia with Lewy bodies. Alzheimer's and Dementia, 2020, 16, e041048.	0.8	2
136	Single-cell profiling of circulating and brain-resident immune cells in a mouse model for amyloidosis and in aged mice. Alzheimer's and Dementia, 2020, 16, e041789.	0.8	0
137	Polygenic risk score for Alzheimer's disease is related to amyloid positivity in subjective cognitive decline: The SCIENCE project. Alzheimer's and Dementia, 2020, 16, e042116.	0.8	0
138	Biomarker testing in MCI patients: Deciding who to tap. Alzheimer's and Dementia, 2020, 16, e042735.	0.8	0
139	Amyloid $\beta$ deposition in cognitively normal oldest-old is associated with cortical thinning and faster memory decline. Alzheimer's and Dementia, 2020, 16, e042768.	0.8	0
140	Gray matter atrophy, but not vascular brain injury is related to cognitive impairment in patients with heart failure. Alzheimer's and Dementia, 2020, 16, e042892.	0.8	0
141	Development of an ultrasensitive multiplex assay for simultaneous detection of A $\beta$ 1-42, A $\beta$ 1-40, GFAP and NF $\kappa$ B in blood. Alzheimer's and Dementia, 2020, 16, e043506.	0.8	2
142	Dutch Brain Research Registry for online study participant recruitment: Design and first results. Alzheimer's and Dementia, 2020, 16, e044738.	0.8	0
143	What patients want to know, and what we actually tell them: The ABIDE project. Alzheimer's and Dementia, 2020, 16, e044754.	0.8	1
144	An RCT to identify best practices for disclosure of amyloid imaging results in mild cognitive impairment: The ABIDE simulation study. Alzheimer's and Dementia, 2020, 16, e044761.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Serum glial fibrillary acidic protein and neurofilament light as prognostic biomarkers for clinical progression in subjective cognitive decline: The SCIENCE project. <i>Alzheimer's and Dementia</i> , 2020, 16, e044783.	0.8	1
146	Trajectories of decline in cognitively complex everyday activities across the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2020, 16, e044787.	0.8	1
147	Using cerebrospinal fluid amyloid $\beta$ (1 $\times$ 42) in the memory clinic: Concordance with PET and use of biomarker ratios across immunoassays. <i>Alzheimer's and Dementia</i> , 2020, 16, e045128.	0.8	3
148	Amyloid pathology, but not vascular pathology, is associated with risk of incident dementia in non-demented memory clinic participants. <i>Alzheimer's and Dementia</i> , 2020, 16, e045196.	0.8	0
149	Grey zone amyloid burden heralds future memory decline: The SCIENCE Project. <i>Alzheimer's and Dementia</i> , 2020, 16, e045210.	0.8	0
150	The evolution of neuropsychiatric symptoms in atypical variants of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e045236.	0.8	2
151	A mixed-methods approach to establish clinically meaningful categories of impairment in instrumental activities of daily living. <i>Alzheimer's and Dementia</i> , 2020, 16, e045693.	0.8	2
152	Educational video increases patients' knowledge regarding the lumbar puncture procedure: Results of a randomized controlled trial in clinical practice. <i>Alzheimer's and Dementia</i> , 2020, 16, e045719.	0.8	0
153	Plasma amyloid $\beta$ oligomerization assay as a screening test for abnormal amyloid status. <i>Alzheimer's and Dementia</i> , 2020, 16, e045754.	0.8	0
154	Identifying and predicting heterogeneity in cognitive decline among individuals with prodromal Alzheimer's disease using a latent class analysis. <i>Alzheimer's and Dementia</i> , 2020, 16, e045829.	0.8	1
155	CSF biomarkers for frontotemporal dementia and its pathological subtypes. <i>Alzheimer's and Dementia</i> , 2020, 16, e045851.	0.8	0
156	Associations of brain connectivity with disease progression and cognitive dysfunction in autosomal-dominant Alzheimer disease depend on imaging modality. <i>Alzheimer's and Dementia</i> , 2020, 16, e045942.	0.8	0
157	Prediction of amyloid PET status using the LUMIPULSE G $\beta$ amyloid ratio (1 $\times$ 42/1 $\times$ 40). <i>Alzheimer's and Dementia</i> , 2020, 16, e046006.	0.8	1
158	Study partner- and self-reported difficulties in cognitively complex everyday activities in participants without objective cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020, 16, e046015.	0.8	0
159	Attitudes towards genetic susceptibility testing for Alzheimer's disease dementia in cognitively normal adults: A survey study. <i>Alzheimer's and Dementia</i> , 2020, 16, e047393.	0.8	2
160	Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 138.	6.2	14
161	CDH6 and HACH protein levels in plasma associate with Alzheimer's disease in APOE $\epsilon$ 4 carriers. <i>Scientific Reports</i> , 2020, 10, 8233.	3.3	17
162	Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3165-3175.	6.4	28

#	ARTICLE	IF	CITATIONS
163	Arylesterase Activity of Paraoxonase-1 in Serum and Cerebrospinal Fluid of Patients with Alzheimer's Disease and Vascular Dementia. <i>Antioxidants</i> , 2020, 9, 456.	5.1	17
164	ATN classification and clinical progression in subjective cognitive decline. <i>Neurology</i> , 2020, 95, e46-e58.	1.1	97
165	Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. <i>Molecular Neurodegeneration</i> , 2020, 15, 36.	10.8	46
166	A Suboptimal Diet Is Associated with Poorer Cognition: The NUDAD Project. <i>Nutrients</i> , 2020, 12, 703.	4.1	21
167	PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. <i>Acta Neuropathologica</i> , 2020, 139, 1025-1044.	7.7	40
168	Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1061-1070.	2.6	13
169	Associations Between Nutrient Intake and Corresponding Nutritional Biomarker Levels in Blood in a Memory Clinic Cohort: The NUDAD Project. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 1436-1438.	2.5	1
170	The Association Between Biomarkers and Neuropsychiatric Symptoms Across the Alzheimer's Disease Spectrum. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 735-744.	1.2	33
171	Non-memory cognitive symptom development in Alzheimer's disease. <i>European Journal of Neurology</i> , 2020, 27, 995-1002.	3.3	7
172	CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1585-1595.	2.6	25
173	The characterisation of subjective cognitive decline. <i>Lancet Neurology</i> , The, 2020, 19, 271-278.	10.2	627
174	Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project. <i>Neurobiology of Aging</i> , 2020, 89, 99-107.	3.1	34
175	Clinicians' communication with patients receiving a MCI diagnosis: The ABIDE project. <i>PLoS ONE</i> , 2020, 15, e0227282.	2.5	19
176	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy. <i>PLoS ONE</i> , 2020, 15, e0226784.	2.5	7
177	Regional [ <sup>18</sup> F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2866-2878.	6.4	29
178	Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 44.	6.2	23
179	Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression. <i>Movement Disorders</i> , 2020, 35, 859-867.	3.9	33
180	What patients want to know, and what we actually tell them: The ABIDE project. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12113.	3.7	9

#	ARTICLE	IF	CITATIONS
181	Specific Nutritional Biomarker Profiles in Mild Cognitive Impairment and Subjective Cognitive Decline Are Associated With Clinical Progression: The NUDAD Project. Journal of the American Medical Directors Association, 2020, 21, 1513.e1-1513.e17.	2.5	17
182	Single-subject gray matter networks predict future cortical atrophy in preclinical Alzheimer's disease. Neurobiology of Aging, 2020, 94, 71-80.	3.1	14
183	Grey matter network trajectories across the Alzheimer's disease continuum and relation to cognition. Brain Communications, 2020, 2, fcaa177.	3.3	10
184	Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimer's Research and Therapy, 2020, 12, 118.	6.2	129
185	Amyloid- $\beta$ misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline. Alzheimer's Research and Therapy, 2020, 12, 169.	6.2	31
186	LDL cholesterol and uridine levels in blood are potential nutritional biomarkers of AD progression: The NUDAD project. Alzheimer's and Dementia, 2020, 16, .	0.8	2
187	LDL cholesterol and uridine levels in blood are potential nutritional biomarkers for clinical progression in Alzheimer's disease: The NUDAD project. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12120.	2.4	7
188	An Operational Definition of "Abnormal Cognition" to Optimize the Prediction of Progression to Dementia: What Are Optimal Cut-Off Points for Univariate and Multivariate Normative Comparisons?. Journal of Alzheimer's Disease, 2020, 77, 1693-1703.	2.6	2
189	Title is missing!. , 2020, 15, e0226784.		0
190	Title is missing!. , 2020, 15, e0226784.		0
191	Title is missing!. , 2020, 15, e0226784.		0
192	Title is missing!. , 2020, 15, e0226784.		0
193	Clinicians' communication with patients receiving a MCI diagnosis: The ABIDE project. , 2020, 15, e0227282.		0
194	Clinicians' communication with patients receiving a MCI diagnosis: The ABIDE project. , 2020, 15, e0227282.		0
195	Clinicians' communication with patients receiving a MCI diagnosis: The ABIDE project. , 2020, 15, e0227282.		0
196	Clinicians' communication with patients receiving a MCI diagnosis: The ABIDE project. , 2020, 15, e0227282.		0
197	Survival in memory clinic cohort is short, even in young-onset dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 726-728.	1.9	22
198	Quantification of [ <sup>18</sup> F]florbetapir: A test-retest tracer kinetic modelling study. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 2172-2180.	4.3	22

#	ARTICLE	IF	CITATIONS
199	The Impact of Frailty and Comorbidity on Institutionalization and Mortality in Persons With Dementia: A Prospective Cohort Study. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 165-170.e2.	2.5	16
200	Energy and Protein Intake of Alzheimer's Disease Patients Compared to Cognitively Normal Controls: Systematic Review. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 14-21.	2.5	17
201	Orthostatic Hypotension: An Important Risk Factor for Clinical Progression to Mild Cognitive Impairment or Dementia. The Amsterdam Dementia Cohort. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 317-325.	2.6	18
202	Added value of amyloid PET in individualized risk predictions for MCI patients. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 529-537.	2.4	8
203	A meta-analysis of genome-wide association studies identifies multiple longevity genes. <i>Nature Communications</i> , 2019, 10, 3669.	12.8	214
204	Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions. <i>Neurobiology of Aging</i> , 2019, 84, 225-234.	3.1	42
205	Clinician-patient communication during the diagnostic workup: The ABIDE project. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 520-528.	2.4	23
206	Pre-analytical stability of novel cerebrospinal fluid biomarkers. <i>Clinica Chimica Acta</i> , 2019, 497, 204-211.	1.1	9
207	Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. <i>Journal of Neurology</i> , 2019, 266, 2535-2545.	3.6	11
208	Applying the ATN scheme in a memory clinic population. <i>Neurology</i> , 2019, 93, e1635-e1646.	1.1	51
209	VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4674.	4.1	26
210	Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project. <i>Alzheimer's and Dementia</i> , 2019, 15, 1458-1467.	0.8	18
211	Amyloid- $\beta^2$ peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 83.	6.2	23
212	Assessing the Pre-Analytical Stability of Small-Molecule Metabolites in Cerebrospinal Fluid Using Direct-Infusion Metabolomics. <i>Metabolites</i> , 2019, 9, 236.	2.9	9
213	Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 492-500.	3.7	5
214	Frequent Cognitive Impairment in Patients With Disorders Along the Heart-Brain Axis. <i>Stroke</i> , 2019, 50, 3369-3375.	2.0	29
215	ABIDE Delphi study: topics to discuss in diagnostic consultations in memory clinics. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 77.	6.2	16
216	Discordant amyloid- $\beta^2$ PET and CSF biomarkers and its clinical consequences. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 78.	6.2	40

#	ARTICLE	IF	CITATIONS
217	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. <i>Lancet Neurology</i> , The, 2019, 18, 1034-1044.	10.2	85
218	Amyloid- $\beta$ Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCE Project. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 7.	3.4	37
219	Associations of AD Biomarkers and Cognitive Performance with Nutritional Status: The NUDAD Project. <i>Nutrients</i> , 2019, 11, 1161.	4.1	25
220	A nonsynonymous mutation in <i>PLCG2</i> reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. <i>Acta Neuropathologica</i> , 2019, 138, 237-250.	7.7	87
221	Trajectories and Determinants of Quality of Life in Dementia with Lewy Bodies and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 389-397.	2.6	30
222	Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and <i>APOE</i> genotype. <i>Alzheimer's and Dementia</i> , 2019, 15, 888-898.	0.8	290
223	Gray matter $T1\rho/T2\rho$ ratios are higher in Alzheimer's disease. <i>Human Brain Mapping</i> , 2019, 40, 3900-3909.	3.6	33
224	$A\beta_{34}$ is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression. <i>Nature Communications</i> , 2019, 10, 2240.	12.8	39
225	High amyloid burden is associated with fewer specific words during spontaneous speech in individuals with subjective cognitive decline. <i>Neuropsychologia</i> , 2019, 131, 184-192.	1.6	22
226	Dietary Patterns Are Related to Clinical Characteristics in Memory Clinic Patients with Subjective Cognitive Decline: The SCIENCE Project. <i>Nutrients</i> , 2019, 11, 1057.	4.1	10
227	Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 33.	6.2	30
228	Impact of a clinical decision support tool on prediction of progression in early-stage dementia: a prospective validation study. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 25.	6.2	23
229	How Do Different Forms of Vascular Brain Injury Relate to Cognition in a Memory Clinic Population: The TRACE-VCI Study. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1273-1286.	2.6	4
230	Standardized Assessment of Automatic Segmentation of White Matter Hyperintensities and Results of the WMH Segmentation Challenge. <i>IEEE Transactions on Medical Imaging</i> , 2019, 38, 2556-2568.	8.9	165
231	ApoE and clusterin CSF levels influence associations between <i>APOE</i> genotype and changes in CSF tau, but not CSF $A\beta_{42}$ , levels in non-demented elderly. <i>Neurobiology of Aging</i> , 2019, 79, 101-109.	3.1	12
232	Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 22, 101786.	2.7	27
233	Clinical relevance of acute cerebral microinfarcts in vascular cognitive impairment. <i>Neurology</i> , 2019, 92, e1558-e1566.	1.1	24
234	Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCE project. <i>Neurobiology of Aging</i> , 2019, 79, 50-58.	3.1	41

#	ARTICLE	IF	CITATIONS
235	Automatically computed rating scales from MRI for patients with cognitive disorders. <i>European Radiology</i> , 2019, 29, 4937-4947.	4.5	23
236	Detecting frontotemporal dementia syndromes using MRI biomarkers. <i>NeuroImage: Clinical</i> , 2019, 22, 101711.	2.7	35
237	Impact of a Clinical Decision Support Tool on Dementia Diagnostics in Memory Clinics: The PredictND Validation Study. <i>Current Alzheimer Research</i> , 2019, 16, 91-101.	1.4	23
238	The Clinical Phenotype of Vascular Cognitive Impairment in Patients with Type 2 Diabetes Mellitus. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 311-322.	2.6	16
239	6071Extent of hypertensive exposure in relation to vascular brain injury and cognitive impairment using heart-brain magnetic resonance imaging; The Heart-Brain Connection Study. <i>European Heart Journal</i> , 2019, 40, .	2.2	0
240	ICâ€Pâ€100: A LONGITUDINAL STUDY OF THE EFFECTS OF EDUCATION AND INTRACRANIAL VOLUME ON COGNITIVE CHANGES AND MORTALITY RATES IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P87.	0.8	0
241	F2â€01â€01: NEURODEVELOPMENTAL DIFFERENCES AND ENVIRONMENTAL INSULTS INVERSELY CORRELATE WITH AGE OF ONSET IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P515.	0.8	0
242	ICâ€Pâ€025: GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2019, 15, P32.	0.8	0
243	Performance of five automated white matter hyperintensity segmentation methods in a multicenter dataset. <i>Scientific Reports</i> , 2019, 9, 16742.	3.3	38
244	ICâ€02â€01: GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2019, 15, P1.	0.8	0
245	ICâ€Pâ€076: FDGâ€PET REVEALS DISTINCT HYPOMETABOLIC TRAJECTORIES IN COGNITIVELYâ€DEFINED SUBGROUPS OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P68.	0.8	0
246	ICâ€Pâ€015: VOXELâ€BASED AMYLOID PET STAGING FOR THE WHOLE ALZHEIMER'S DISEASE <i>CONTINUUM</i>. <i>Alzheimer's and Dementia</i> , 2019, 15, P24.	0.8	0
247	P1â€291: THE ASSOCIATION BETWEEN AFFECTIVE SYMPTOMS AND ALZHEIMER'S DISEASE BIOMARKERS ACROSS THE DISEASE SPECTRUM. <i>Alzheimer's and Dementia</i> , 2019, 15, P355.	0.8	0
248	High occurrence of transportation and logistics occupations among vascular dementia patients: an observational study. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 112.	6.2	5
249	PET and CSF amyloid-Î² status are differently predicted by patient features: information from discordant cases. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 100.	6.2	21
250	Subjective cognitive decline and rates of incident Alzheimer's disease and nonâ€Alzheimer's disease dementia. <i>Alzheimer's and Dementia</i> , 2019, 15, 465-476.	0.8	232
251	Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 1-9.	2.4	14
252	Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimerâ€™s disease risk. <i>Nature Genetics</i> , 2019, 51, 404-413.	21.4	1,625

#	ARTICLE	IF	CITATIONS
253	Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease. <i>Human Brain Mapping</i> , 2019, 40, 638-651.	3.6	27
254	Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease—Data from three memory clinic studies. <i>Alzheimer's and Dementia</i> , 2019, 15, 185-193.	0.8	28
255	Nature and implications of sex differences in AD pathology. <i>Nature Reviews Neurology</i> , 2019, 15, 6-8.	10.1	17
256	Repeat length variations in ATXN1 and AR modify disease expression in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 73, 230.e9-230.e17.	3.1	7
257	Centenarian controls increase variant effect sizes by an average twofold in an extreme case—extreme control analysis of Alzheimer's disease. <i>European Journal of Human Genetics</i> , 2019, 27, 244-253.	2.8	46
258	Impact of white matter hyperintensity location on depressive symptoms in memory-clinic patients: a lesion-symptom mapping study. <i>Journal of Psychiatry and Neuroscience</i> , 2019, 44, E1-E10.	2.4	9
259	Web-Based Multidomain Lifestyle Programs for Brain Health: Comprehensive Overview and Meta-Analysis. <i>JMIR Mental Health</i> , 2019, 6, e12104.	3.3	36
260	Development and Usability of ADappt: Web-Based Tool to Support Clinicians, Patients, and Caregivers in the Diagnosis of Mild Cognitive Impairment and Alzheimer Disease. <i>JMIR Formative Research</i> , 2019, 3, e13417.	1.4	38
261	Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. <i>Neurology</i> , 2018, 90, e1231-e1239.	1.1	94
262	Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. <i>Clinical Chemistry</i> , 2018, 64, 927-937.	3.2	37
263	Wishes and preferences for an online lifestyle program for brain health—A mixed methods study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 141-149.	3.7	11
264	Time Trend in Persistent Cognitive Decline: Results From the Longitudinal Aging Study Amsterdam. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2018, 73, S57-S64.	3.9	18
265	Long-Term Prognostic Implications of Previous Silent Myocardial Infarction in Patients Presenting With Acute Myocardial Infarction. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1773-1781.	5.3	41
266	Single Subject Classification of Alzheimer's Disease and Behavioral Variant Frontotemporal Dementia Using Anatomical, Diffusion Tensor, and Resting-State Functional Magnetic Resonance Imaging. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1827-1839.	2.6	33
267	A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline. <i>Human Brain Mapping</i> , 2018, 39, 3143-3151.	3.6	40
268	Vascular cognitive impairment. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18003.	30.5	358
269	Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer's Disease. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2018, 3, 463-472.	1.5	41
270	Microbleeds are associated with depressive symptoms in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 112-120.	2.4	7

#	ARTICLE	IF	CITATIONS
271	Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies. <i>Alzheimer's and Dementia</i> , 2018, 14, 707-722.	0.8	143
272	Disease-related determinants are associated with mortality in dementia due to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 23.	6.2	20
273	European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials. <i>Alzheimer's and Dementia</i> , 2018, 14, 837-842.	0.8	20
274	Prevalence of the apolipoprotein E $\epsilon$ 4 allele in amyloid $\beta$ positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.8	58
275	Thinner cortex in patients with subjective cognitive decline is associated with steeper decline of memory. <i>Neurobiology of Aging</i> , 2018, 61, 238-244.	3.1	23
276	Gray matter networks and clinical progression in subjects with predementia Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 61, 75-81.	3.1	52
277	The Missing Link in the Pathophysiology of Vascular Cognitive Impairment: Design of the Heart-Brain Study. <i>Cerebrovascular Diseases Extra</i> , 2018, 7, 140-152.	1.5	44
278	Gray matter network measures are associated with cognitive decline in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2018, 61, 198-206.	3.1	44
279	Association of Cerebral Amyloid- $\beta$ Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	11.0	133
280	Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid- $\beta$ 1-42 Analysis Results. <i>Clinical Chemistry</i> , 2018, 64, 576-585.	3.2	126
281	Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. <i>Neurology</i> , 2018, 90, e149-e156.	1.1	103
282	P1-256: COMMUNICATION ON DIAGNOSTIC TESTING FOR (ALZHEIMER'S) DEMENTIA: THE ABIDE-CLINICAL ENCOUNTER STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P378.	0.8	0
283	P3-403: LOSS OF GREY MATTER CONNECTIVITY IN THE PRECUNEUS IS ASSOCIATED WITH FASTER ATROPHY RATES IN PRECLINICAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1257.	0.8	0
284	O1-10-06: CONTACTIN-1 HAS ADDED VALUE FOR DISCRIMINATION OF DEMENTIA WITH LEWY BODIES FROM ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P245.	0.8	0
285	P1-476: CORTICAL T1W/T2W RATIO VALUES ARE HIGHER IN ALZHEIMER'S DISEASE COMPARED TO CONTROLS. <i>Alzheimer's and Dementia</i> , 2018, 14, P506.	0.8	0
286	O1-14-04: IMPACT OF WHITE MATTER HYPERINTENSITY LOCATION ON DEPRESSIVE SYMPTOMS IN MEMORY CLINIC PATIENTS: A LESION-SYMPTOM MAPPING STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P259.	0.8	0
287	IC-P-111: [ <sup>18</sup> F]FLORBETAPIR-SPECIFIC BINDING IN RELATION TO COGNITION IN SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2018, 14, P95.	0.8	0
288	IC-P-222: [18F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM. <i>Alzheimer's and Dementia</i> , 2018, 14, P180.	0.8	0

#	ARTICLE	IF	CITATIONS
289	P1â€³28: CONSISTENCY OF MUISTIKKO WEBâ€³BASED COGNITIVE TEST WHILE PERFORMED AT CLINIC AND AT HOME. Alzheimer's and Dementia, 2018, 14, P418.	0.8	0
290	P2â€³645: IMPAIRED OLFACTORY AND GUSTATORY FUNCTIONING IN PATIENTS WITH ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT: THE NUDAD PROJECT. Alzheimer's and Dementia, 2018, 14, P990.	0.8	1
291	P2â€³350: DETECTING FRONTOTEMPORAL DEMENTIA USING A NOVEL MRI IMAGING BIOMARKER: THE ANTERIOR VERSUS POSTERIOR INDEX. Alzheimer's and Dementia, 2018, 14, P821.	0.8	0
292	P1â€³357: MEDIAN SURVIVAL IN MEMORY CLINIC COHORT IS SHORT, EVEN IN YOUNGâ€³ONSET DEMENTIA. Alzheimer's and Dementia, 2018, 14, P431.	0.8	0
293	P1â€³016: METHYLPHENIDATE IMPROVES EXECUTIVE FUNCTIONING IN PATIENTS WITH VASCULAR COGNITIVE IMPAIRMENT: FIRST RESULTS OF THE STREAMâ€³VCI STUDY. Alzheimer's and Dementia, 2018, 14, P270.	0.8	0
294	P1â€³259: SEX DIFFERENCES IN CEREBROSPINAL FLUID BIOMARKER CONCENTRATIONS ACROSS CLINICAL STAGES OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P380.	0.8	0
295	O2â€³06â€³03: AMYLOIDâ€³ $\beta$ LOAD IS RELATED TO WORRIES IN INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P632.	0.8	0
296	P2â€³248: CONTACTINâ€³2 AS A POTENTIAL BIOMARKER FOR MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2018, 14, P768.	0.8	0
297	ICâ€³06â€³05: LOSS OF GREY MATTER CONNECTIVITY IN THE PRECUNELUS IS ASSOCIATED WITH FASTER ATROPHY RATES IN PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P13.	0.8	0
298	P2â€³228: PREâ€³ANALYTICAL STABILITY OF NOVEL CEREBROSPINAL FLUID BIOMARKERS FOR DEMENTIA. Alzheimer's and Dementia, 2018, 14, P755.	0.8	0
299	ICâ€³Pâ€³092: COGNITIVELY DEFINED SUBTYPES OF ALZHEIMER'S DISEASE ARE ASSOCIATED WITH DISTINCT PATTERNS OF ATROPHY. Alzheimer's and Dementia, 2018, 14, P76.	0.8	1
300	P3â€³134: CIRCULATING METABOLITES ARE ASSOCIATED WITH WHITE MATTER HYPERINTENSITIES. Alzheimer's and Dementia, 2018, 14, P1119.	0.8	0
301	P4â€³106: DECLINE IN GREY MATTER CONNECTIVITY OVER TIME IS RELATED TO CLINICAL PROGRESSION IN MCI DUE TO AD. Alzheimer's and Dementia, 2018, 14, P1479.	0.8	1
302	P1â€³297: METABOLIC BLOODâ€³BASED BIOMARKERS RELATE TO BRAIN ATROPHY AND WHITE MATTER HYPERINTENSITIES IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P401.	0.8	0
303	P3â€³438: PARAMETRIC IMAGING OF [ <sup>18</sup> F]FLORBETAPIR: A TESTâ€³RETEST STUDY IN HEALTHY SUBJECTS AND PATIENTS WITH ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1281.	0.8	0
304	P3â€³289: HARMONIZATION OF SCD OPERATIONALIZATION ACROSS DIFFERENT MEMORY CLINIC SETTINGS: THE EUROâ€³SCD STUDY. Alzheimer's and Dementia, 2018, 14, P1191.	0.8	0
305	O2â€³09â€³03: DIAGNOSTIC PERFORMANCE OF ELECSYS IMMUNOASSAYS FOR CEREBROSPINAL FLUID ALZHEIMER'S DISEASE BIOMARKERS IN A NONâ€³ACADEMIC MULTICENTER MEMORY CLINIC COHORT: THE ABIDE PROJECT. Alzheimer's and Dementia, 2018, 14, P641.	0.8	0
306	P2â€³349: DIFFERENT COMBINATIONS OF DIAGNOSTIC TESTS DISCRIMINATE SPECIFIC SUBTYPES OF DEMENTIA. Alzheimer's and Dementia, 2018, 14, P820.	0.8	0

#	ARTICLE	IF	CITATIONS
307	P2â€³52: COMMUNICATING UNCERTAINTY WHEN DISCLOSING DIAGNOSTIC TEST RESULT: THE ABIDEâ€³CLINICAL ENCOUNTER STUDY. Alzheimer's and Dementia, 2018, 14, P823.	0.8	0
308	P1â€³656: NUTRITIONAL STATUS AND BODY COMPOSITION OF PATIENTS WITH AD, MCI AND SUBJECTIVE COGNITIVE DECLINE: THE NUDAD PROJECT. Alzheimer's and Dementia, 2018, 14, P593.	0.8	0
309	P2â€³63: LATENT ATROPHY FACTORS IN POSTERIOR CORTICAL ATROPHY RELATE TO SPECIFIC COGNITIVE IMPAIRMENTS. Alzheimer's and Dementia, 2018, 14, P830.	0.8	0
310	P2â€³134: THE ADDED VALUE OF EXTREME PHENOTYPES IN ALZHEIMER'S DISEASE CASEâ€³CONTROL STUDIES. Alzheimer's and Dementia, 2018, 14, P719.	0.8	0
311	P2â€³60: [ <sup>18</sup> F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM. Alzheimer's and Dementia, 2018, 14, P827.	0.8	0
312	P3â€³264: UNBIASED METHOD TO DETERMINE CUTâ€³POINTS FOR CSF TOTAL TAU LEVELS REVEALS PRESENCE OF BIOLOGICAL SUBTYPES IN A LARGE ALZHEIMER'S DISEASE POPULATION. Alzheimer's and Dementia, 2018, 14, P1176.	0.8	0
313	O2â€³03â€³03: COGNITIVELY DEFINED SUBTYPES OF ALZHEIMER'S DISEASE ARE ASSOCIATED WITH DISTINCT PATTERNS OF ATROPHY. Alzheimer's and Dementia, 2018, 14, P615.	0.8	0
314	P4â€³038: IS <i>SORL1</i> AN AUTOSOMAL DOMINANT ALZHEIMER GENE?. Alzheimer's and Dementia, 2018, 14, P1447.	0.8	0
315	P2â€³500: PHYSICAL PERFORMANCE IN RELATION TO COGNITIVE FUNCTIONING IN PATIENTS WITH DISORDERS ALONG THE HEARTâ€³BRAIN AXIS. Alzheimer's and Dementia, 2018, 14, P921.	0.8	0
316	O2â€³06â€³01: [ <sup>18</sup> F]FLORBETAPIR SPECIFIC BINDING IN RELATION TO COGNITION IN SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P630.	0.8	0
317	O5â€³04â€³01: A RARE GENETIC VARIANT IN THE <i>PLCG2</i> GENE IS ASSOCIATED WITH A REDUCED RISK OF ALL MAJOR TYPES OF DEMENTIA AND AN INCREASED RISK TO REACH AN EXTREMELY OLD AGE. Alzheimer's and Dementia, 2018, 14, P1648.	0.8	0
318	ICâ€³Paâ€³093: LATENT ATROPHY FACTORS IN POSTERIOR CORTICAL ATROPHY RELATE TO SPECIFIC COGNITIVE IMPAIRMENTS. Alzheimer's and Dementia, 2018, 14, P79.	0.8	0
319	ICâ€³Paâ€³033: LONGITUDINAL CHANGES IN GREY MATTER CONNECTIVITY ARE RELATED TO COGNITIVE DECLINE IN PRODROMAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P37.	0.8	0
320	P3â€³342: INFLUENCE OF NETWORK CONSTRUCTION METHODS ON PATH LENGTH VALUES IN ALZHEIMER'S DISEASE: A MULTIâ€³STUDY ANALYSIS OF MRI CONNECTIVITY STUDIES. Alzheimer's and Dementia, 2018, 14, P1214.	0.8	0
321	ICâ€³Paâ€³032: INFLUENCE OF NETWORK CONSTRUCTION METHODS ON PATH LENGTH VALUES IN ALZHEIMER'S DISEASE: A MULTIâ€³STUDY ANALYSIS OF MRI CONNECTIVITY STUDIES. Alzheimer's and Dementia, 2018, 14, P36.	0.8	0
322	ICâ€³Paâ€³192: DISEASEâ€³STAGE SPECIFIC RELATIONSHIP BETWEEN COGNITIVE RESERVE AND CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P158.	0.8	2
323	F5â€³05â€³04: THE USE OF RESIDUAL METHODS TO CAPTURE COGNITIVE RESERVE AND STUDY CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1633.	0.8	0
324	P1â€³467: DISEASEâ€³STAGEâ€³SPECIFIC RELATIONSHIP BETWEEN COGNITIVE RESERVE AND CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P500.	0.8	0

#	ARTICLE	IF	CITATIONS
325	O3â€13â€06: TAKING AMYLOID PET INTO THE CLINIC: INDIVIDUALIZED RISK PREDICTION IN MCI PATIENTS â€” THE ABIDE PROJECT. Alzheimer's and Dementia, 2018, 14, P1058.	0.8	0
326	O2â€15â€06: CSF AMYLOIDâ€2 PEPTIDES IN DEMENTIA WITH LEWY BODIES AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P663.	0.8	0
327	O3â€14â€03: IDENTIFICATION OF NOVEL CEREBROSPINAL FLUID BIOMARKER CANDIDATES FOR DEMENTIA WITH LEWY BODIES: A PROTEOMIC APPROACH. Alzheimer's and Dementia, 2018, 14, P1060.	0.8	0
328	O2â€15â€04: ROBUST INDIVIDUALIZED PREDICTION MODELS WHICH ARE APPLICABLE ACROSS DIFFERENT COHORTS. Alzheimer's and Dementia, 2018, 14, P661.	0.8	0
329	O5â€01â€03: ATROPHY SUBTYPES IN ALZHEIMER'S DISEASE IDENTIFIED THROUGH NONâ€NEGATIVE MATRIX FACTORIZATION. Alzheimer's and Dementia, 2018, 14, P1638.	0.8	0
330	P2â€28â€4: NUTRITIONAL MARKERS ASSOCIATED WITH CLINICAL PROGRESSION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND SUBJECTIVE COGNITIVE DECLINE: THE NUDAD STUDY. Alzheimer's and Dementia, 2018, 14, P789.	0.8	0
331	P1â€60â€2: DUTCH ONLINE REGISTRY FOR RECRUITMENT OF PARTICIPANTS FOR DEMENTIA STUDIES: HERSENONDERZOEK.NL AND BRAIN HEALTH REGISTRY. Alzheimer's and Dementia, 2018, 14, P569.	0.8	1
332	P3â€61â€7: NUTRITIONAL INTAKE IN SUBJECTIVE COGNITIVE DECLINE: ROOM FOR IMPROVEMENT?. Alzheimer's and Dementia, 2018, 14, P1366.	0.8	0
333	F4â€08â€01: PLASMA AMYLOID AS A PREâ€SCREENING TOOL FOR AMYLOID POSITIVITY IN SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P1394.	0.8	0
334	Î±â€Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies. Movement Disorders, 2018, 33, 1724-1733.	3.9	79
335	Computerâ€assisted prediction of clinical progression in the earliest stages of AD. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 726-736.	2.4	8
336	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result. Frontiers in Aging Neuroscience, 2018, 10, 409.	3.4	28
337	Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 563-572.	2.4	52
338	Prevalence of amyloidâ€2 pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	5.3	132
339	Cerebral Blood Flow and Cognitive Functioning in a Community-Based, Multi-Ethnic Cohort: The SABRE Study. Frontiers in Aging Neuroscience, 2018, 10, 279.	3.4	61
340	Atrophy subtypes in prodromal Alzheimerâ€™s disease are associated with cognitive decline. Brain, 2018, 141, 3443-3456.	7.6	102
341	ICâ€Pâ€187: CORTICAL T1â€W/T2â€W RATIO VALUES ARE HIGHER IN ALZHEIMER'S DISEASE COMPARED TO CONTROLS. Alzheimer's and Dementia, 2018, 14, P156.	0.8	0
342	Clinical phenotype, atrophy, and small vessel disease in <i>APOE</i> Î²2 carriers with Alzheimer disease. Neurology, 2018, 91, e1851-e1859.	1.1	46

#	ARTICLE	IF	CITATIONS
343	Plasma Amyloid as Prescreener for the Earliest <sc>A</sc> Alzheimer Pathological Changes. Annals of Neurology, 2018, 84, 648-658.	5.3	230
344	Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. Neurolmage: Clinical, 2018, 19, 625-632.	2.7	23
345	Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 64, 631-642.	2.6	20
346	Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. Alzheimer's Research and Therapy, 2018, 10, 72.	6.2	34
347	Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. Alzheimer's Research and Therapy, 2018, 10, 58.	6.2	21
348	Pre-amyloid stage of Alzheimer's disease in cognitively normal individuals. Annals of Clinical and Translational Neurology, 2018, 5, 1037-1047.	3.7	23
349	Amsterdam Dementia Cohort: Performing Research to Optimize Care. Journal of Alzheimer's Disease, 2018, 62, 1091-1111.	2.6	228
350	Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 52.	6.2	18
351	Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier. Frontiers in Aging Neuroscience, 2018, 10, 111.	3.4	29
352	Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. Frontiers in Aging Neuroscience, 2018, 10, 67.	3.4	29
353	Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 5.	6.2	94
354	Evaluating combinations of diagnostic tests to discriminate different dementia types. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 509-518.	2.4	19
355	Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change. Journal of Psychiatric Research, 2018, 104, 183-191.	3.1	21
356	Prominent Non-Memory Deficits in Alzheimer's Disease Are Associated with Faster Disease Progression. Journal of Alzheimer's Disease, 2018, 65, 1029-1039.	2.6	14
357	Subjective Cognitive Impairment Cohort (SCIENCE): study design and first results. Alzheimer's Research and Therapy, 2018, 10, 76.	6.2	87
358	Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort. JAMA Neurology, 2018, 75, 1062.	9.0	102
359	Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial. JMIR Research Protocols, 2018, 7, e80.	1.0	3
360	Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment. Molecular Psychiatry, 2017, 22, 153-160.	7.9	102

#	ARTICLE	IF	CITATIONS
361	Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 687-697.	2.6	60
362	Screening for Mild Cognitive Impairment and Dementia with Automated, Anonymous Online and Telephone Cognitive Self-Tests. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 249-259.	2.6	18
363	Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 143-151.	2.4	57
364	Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. <i>Alzheimer's and Dementia</i> , 2017, 13, 903-912.	0.8	32
365	Non-Pharmacologic Interventions for Older Adults with Subjective Cognitive Decline: Systematic Review, Meta-Analysis, and Preliminary Recommendations. <i>Neuropsychology Review</i> , 2017, 27, 245-257.	4.9	97
366	Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 113-118.	1.9	100
367	Consensus classification of posterior cortical atrophy. <i>Alzheimer's and Dementia</i> , 2017, 13, 870-884.	0.8	423
368	Gait Speed and Grip Strength Reflect Cognitive Impairment and Are Modestly Related to Incident Cognitive Decline in Memory Clinic Patients With Subjective Cognitive Decline and Mild Cognitive Impairment: Findings From the 4C Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2017, 72, 846-854.	3.6	69
369	Quantification of Tau Load Using [18F]AV1451 PET. <i>Molecular Imaging and Biology</i> , 2017, 19, 963-971.	2.6	42
370	Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts. <i>Alzheimer's and Dementia</i> , 2017, 13, 1226-1236.	0.8	59
371	CSF ApoE predicts clinical progression in nondemented APOE $\epsilon$ 4 carriers. <i>Neurobiology of Aging</i> , 2017, 57, 186-194.	3.1	26
372	The need for harmonisation and innovation of neuropsychological assessment in neurodegenerative dementias in Europe: consensus document of the Joint Program for Neurodegenerative Diseases Working Group. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 27.	6.2	66
373	Effect of long-term storage in biobanks on cerebrospinal fluid biomarker A $\beta$ <sub>42</sub> , T $\alpha$ u, and P $\alpha$ u values. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 45-50.	2.4	21
374	Rare Genetic Variant in SORL1 May Increase Penetrance of Alzheimer's Disease in a Family with Several Generations of APOE $\epsilon$ 4 Homozygosity. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 63-74.	2.6	32
375	The blood brain barrier in Alzheimer's disease. <i>Vascular Pharmacology</i> , 2017, 89, 12-18.	2.1	84
376	Patients' and caregivers' views on conversations and shared decision making in diagnostic testing for Alzheimer's disease: The ABIDE project. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 314-322.	3.7	47
377	Diagnostic dilemmas in Alzheimer's disease: Room for shared decision making. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 301-304.	3.7	28
378	A neuroimaging approach to capture cognitive reserve: Application to Alzheimer's disease. <i>Human Brain Mapping</i> , 2017, 38, 4703-4715.	3.6	59

#	ARTICLE	IF	CITATIONS
379	Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 139-146.	2.4	19
380	Alzheimer's disease: The state of the art in resting-state magnetoencephalography. <i>Clinical Neurophysiology</i> , 2017, 128, 1426-1437.	1.5	76
381	Characterization of pathogenic SORL1 genetic variants for association with Alzheimer's disease: a clinical interpretation strategy. <i>European Journal of Human Genetics</i> , 2017, 25, 973-981.	2.8	102
382	Clinicians' views on conversations and shared decision making in diagnostic testing for Alzheimer's disease: The ABIDE project. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 305-313.	3.7	23
383	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 111-126.	2.4	197
384	Selective impairment of hippocampus and posterior hub areas in Alzheimer's disease: an MEG-based multiplex network study. <i>Brain</i> , 2017, 140, 1466-1485.	7.6	132
385	Design of the ExCersion-VC study: The effect of aerobic exercise on cerebral perfusion in patients with vascular cognitive impairment. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 157-165.	3.7	15
386	Low normal cerebrospinal fluid A $\beta$ 42 levels predict clinical progression in nondemented subjects. <i>Annals of Neurology</i> , 2017, 81, 749-753.	5.3	20
387	The Pitfall of Behavioral Variant Frontotemporal Dementia Mimics Despite Multidisciplinary Application of the FTDC Criteria. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 959-975.	2.6	34
388	Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project. <i>JAMA Neurology</i> , 2017, 74, 1481.	9.0	77
389	A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 13333.	3.3	45
390	[ICP-130]: MRI-BASED CLASSIFICATION ACCURACY OF DEMENTIA TYPE IS DETERMINED BY MRI MODALITY. <i>Alzheimer's and Dementia</i> , 2017, 13, P98.	0.8	0
391	[P1-392]: AUTOMATED SELECTION OF MULTIMODAL MRI BIOMARKERS FOR DIAGNOSIS OF DEMENTIA. <i>Alzheimer's and Dementia</i> , 2017, 13, P417.	0.8	0
392	Blood-based metabolic signatures in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 196-207.	2.4	56
393	Directional information flow in patients with Alzheimer's disease. A source-space resting-state MEG study. <i>NeuroImage: Clinical</i> , 2017, 15, 673-681.	2.7	33
394	Lumbar puncture in patients with neurologic conditions. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 108-110.	2.4	12
395	Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 9, 76-83.	2.4	39
396	EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects. <i>Neurobiology of Aging</i> , 2017, 57, 133-142.	3.1	91

#	ARTICLE	IF	CITATIONS
397	Diagnostic impact of [18F]flutemetamol PET in early-onset dementia. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 2.	6.2	98
398	Implementation of subjective cognitive decline criteria in research studies. <i>Alzheimer's and Dementia</i> , 2017, 13, 296-311.	0.8	375
399	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2017, 49, 214.e13-214.e15.	3.1	12
400	Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 531-540.	0.8	99
401	Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer's disease. <i>European Radiology</i> , 2017, 27, 1169-1175.	4.5	97
402	A novel <i>CCM2</i> variant in a family with non-progressive cognitive complaints and cerebral microbleeds. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2017, 174, 220-226.	1.7	6
403	[P14243]: ALPHA-SYNUCLEIN SPECIES AS POTENTIAL CSF BIOMARKERS FOR DEMENTIA WITH LEWY BODIES. <i>Alzheimer's and Dementia</i> , 2017, 13, P338.	0.8	2
404	[P14009]: DETECTING COGNITIVE DISORDERS USING THE MUISTIKKO WEB-BASED COGNITIVE TEST BATTERY: VALIDATION IN THREE COHORTS. <i>Alzheimer's and Dementia</i> , 2017, 13, P234.	0.8	0
405	[P34473]: THE EFFECTS OF AMYLOID ON SEMANTIC COMPLEXITY IN SPONTANEOUS SPEECH IN SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2017, 13, P821.	0.8	0
406	[P34161]: GRANULOCYTES: KEY PLAYERS IN PERIPHERAL A $\beta$ 2 CLEARANCE?. <i>Alzheimer's and Dementia</i> , 2017, 13, P995.	0.8	0
407	[P34226]: PROFILING PERIPHERAL METABOLIC DYSREGULATION IN ALZHEIMER'S DISEASE: THE ADDED VALUE OF MULTIPLE SIGNATURES. <i>Alzheimer's and Dementia</i> , 2017, 13, P1024.	0.8	0
408	[P34375]: GREY MATTER CONNECTIVITY IS ASSOCIATED WITH THE RATE OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2017, 13, P1102.	0.8	0
409	[P34386]: COMPUTED RATING SCALES FOR COGNITIVE DISORDERS FROM MRI. <i>Alzheimer's and Dementia</i> , 2017, 13, P1108.	0.8	1
410	[P34407]: SUBJECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH ALTERED POSTERIOR CINGULATE CONNECTIVITY IN ELDERLY WITH A FAMILIAL HISTORY OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1120.	0.8	0
411	[P34422]: CLINICAL AND RADIOLOGICAL FINDINGS IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CAA. <i>Alzheimer's and Dementia</i> , 2017, 13, P1127.	0.8	0
412	[P34566]: IMPROVING BRAIN HEALTH THROUGH AN ONLINE LIFESTYLE PROGRAM: PREFERENCES OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1195.	0.8	0
413	[P44219]: [ <sup>18</sup> F]AV1451 BINDING POTENTIAL IN RELATION TO AMYLOID STATUS AND COGNITION IN SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1352.	0.8	0
414	[P44235]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER'S PATIENTS AND CONTROLS USING FLORTAUCIPIR. <i>Alzheimer's and Dementia</i> , 2017, 13, P1364.	0.8	0

#	ARTICLE	IF	CITATIONS
415	[ICâ€Pâ€005]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOIDâ€² AND [ <sup>18</sup> F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS. Alzheimer's and Dementia, 2017, 13, P13.	0.8	1
416	[ICâ€Pâ€037]: SUBJECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH ALTERED POSTERIOR CINGULATE CONNECTIVITY IN ELDERLY WITH A FAMILIAL HISTORY OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P33.	0.8	0
417	[ICâ€Pâ€055]: EFFECT OF APOEâ€² ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P45.	0.8	0
418	[ICâ€Pâ€085]: GREY MATTER CONNECTIVITY IS ASSOCIATED WITH THE RATE OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P69.	0.8	0
419	[ICâ€Pâ€095]: MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P74.	0.8	0
420	[ICâ€Pâ€106]: PREDICTING PROGRESSION IN PREâ€DEMENTIA STAGES OF ALZHEIMER'S DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE. Alzheimer's and Dementia, 2017, 13, P81.	0.8	0
421	[ICâ€Pâ€110]: GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P87.	0.8	0
422	[ICâ€Pâ€203]: [ <sup>18</sup> F]AV1451 BINDING POTENTIAL IN RELATION TO AMYLOID STATUS AND COGNITION IN SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P148.	0.8	0
423	[ICâ€Pâ€206]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER'S PATIENTS AND CONTROLS USING FLORTAUCIPiR. Alzheimer's and Dementia, 2017, 13, P150.	0.8	0
424	[TDâ€Pâ€020]: IMPROVING BRAIN HEALTH THROUGH AN ONLINE LIFESTYLE PROGRAM: PREFERENCES OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P166.	0.8	0
425	[P1â€250]: DECISION TREE ANALYSIS REVEALS TWO CUTâ€OFF LEVELS FOR AMYLOID BETA IN EARLY AD DIAGNOSIS. Alzheimer's and Dementia, 2017, 13, P342.	0.8	0
426	[P1â€326]: DETECTING COGNITIVE DISORDERS USING MUISTIKKO WEBâ€BASED COGNITIVE TEST BATTERY: VALIDATION IN THREE COHORTS. Alzheimer's and Dementia, 2017, 13, P380.	0.8	0
427	[P1â€375]: DATAâ€DRIVEN DIAGNOSIS OF DEMENTIA DISORDERS: THE PREDICTND VALIDATION STUDY. Alzheimer's and Dementia, 2017, 13, P405.	0.8	2
428	[P1â€440]: GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P451.	0.8	0
429	[P1â€486]: OCCURRENCE AND PROFILE OF COGNITIVE IMPAIRMENT IN PATIENTS WITH HEART FAILURE, CAROTID OCCLUSIVE DISEASE AND VASCULAR COGNITIVE IMPAIRMENT: THE HEARTâ€BRAIN CONNECTION STUDY. Alzheimer's and Dementia, 2017, 13, P475.	0.8	0
430	[P2â€052]: THE DUTCH BRAIN HEALTH REGISTRY: OPTIMIZING RECRUITMENT FOR DEMENTIA RESEARCH. Alzheimer's and Dementia, 2017, 13, P624.	0.8	3
431	[P2â€207]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOIDâ€² AND [ <sup>18</sup> F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS. Alzheimer's and Dementia, 2017, 13, P688.	0.8	0
432	[P2â€242]: PROTEOMICS IDENTIFICATION OF NOVEL CEREBROSPINAL FLUID BIOMARKER CANDIDATES OF DEMENTIA WITH LEWY BODIES. Alzheimer's and Dementia, 2017, 13, P704.	0.8	0

#	ARTICLE	IF	CITATIONS
433	[P2â€“249]: CONTACTINâ€“1 IN CSF DISCRIMINATES DEMENTIA WITH LEWY BODIES (DLB) FROM AD AND NONâ€“DEMENTED CONTROLS. Alzheimer's and Dementia, 2017, 13, P708.	0.8	0
434	[P2â€“335]: EFFECT OF APOE Î²2 ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P748.	0.8	0
435	[F1â€“03â€“04]: BIOMARKERâ€“BASED PERSONALIZED RISK ESTIMATES FOR PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P177.	0.8	0
436	[O1â€“01â€“02]: MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P182.	0.8	0
437	[O1â€“05â€“03]: CSF AMYLOID BETA 1â€“42 LEVELS OBTAINED OVER 15 YEARS SHOW A DIAGNOSISâ€“DEPENDENT UPWARD DRIFT. Alzheimer's and Dementia, 2017, 13, P198.	0.8	0
438	[O1â€“05â€“04]: CLINICAL PERFORMANCE OF NEUROGRANIN AS A CEREBROSPINAL FLUID BIOMARKER FOR ALZHEIMER'S DISEASE: AN ASSAY COMPARISON STUDY. Alzheimer's and Dementia, 2017, 13, P199.	0.8	0
439	[O2â€“01â€“01]: CHARACTERIZING INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE: THE SUBJECTIVE COGNITIVE IMPAIRMENT COHORT (SCIENCE). Alzheimer's and Dementia, 2017, 13, P547.	0.8	0
440	[O2â€“10â€“06]: PROGNOSIS OF CLINICAL PROGRESSION IN SUBJECTIVE COGNITIVE DECLINE USING A CLINICAL DECISION SUPPORT SYSTEM. Alzheimer's and Dementia, 2017, 13, P579.	0.8	0
441	[O2â€“11â€“03]: PREDICTING PROGRESSION IN PREâ€“DEMENTIA STAGES OF ALZHEIMER'S DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE. Alzheimer's and Dementia, 2017, 13, P581.	0.8	0
442	[O2â€“12â€“03]: DURATION OF ALZHEIMER'S DISEASE IN THE PRECLINICAL, PRODROMAL AND DEMENTIA STAGE: A MULTIâ€“STATE MODEL ANALYSIS. Alzheimer's and Dementia, 2017, 13, P585.	0.8	4
443	[O3â€“06â€“04]: PROMINENT NONâ€“MEMORY DEFICITS IN AD ARE ASSOCIATED WITH A FASTER DISEASE PROGRESSION. Alzheimer's and Dementia, 2017, 13, P912.	0.8	0
444	[P4â€“525]: DATAâ€“DRIVEN TAUâ€“PET COVARIANCE NETWORKS ENHANCE PREDICTION OF RETROSPECTIVE COGNITIVE CHANGE IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1548.	0.8	1
445	[DTâ€“01â€“02]: THE IMPACT OF AMYLOID PET ON DIAGNOSIS AND PATIENT MANAGEMENT IN AN UNSELECTED MEMORY CLINIC COHORT: THE ABIDE PROJECT. Alzheimer's and Dementia, 2017, 13, P1474.	0.8	0
446	Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 61, 309-320.	2.6	27
447	[P3â€“075]: PLEIOTROPHIN, A NEW BIOMARKER FOR AD, IDENTIFIED USING A NOVEL STRATEGY IN CLINICAL PROTEOMICS. Alzheimer's and Dementia, 2017, 13, P960.	0.8	0
448	MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis. Frontiers in Aging Neuroscience, 2017, 9, 117.	3.4	71
449	Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. Alzheimer's Research and Therapy, 2017, 9, 73.	6.2	25
450	Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. Alzheimer's Research and Therapy, 2017, 9, 101.	6.2	43

#	ARTICLE	IF	CITATIONS
451	Detection of contactin-2 in cerebrospinal fluid (CSF) of patients with Alzheimer's disease using Fluorescence Correlation Spectroscopy (FCS). Clinical Biochemistry, 2017, 50, 1061-1066.	1.9	16
452	Vascular Cognitive Impairment in a Memory Clinic Population: Rationale and Design of the "Utrecht-Amsterdam Clinical Features and Prognosis in Vascular Cognitive Impairment" (TRACE-VCI) Study. JMIR Research Protocols, 2017, 6, e60.	1.0	29
453	Subjective Memory Complaints in APOE $\epsilon$ 4 Carriers are Associated with High Amyloid- $\beta$ Burden. Journal of Alzheimer's Disease, 2016, 49, 1115-1122.	2.6	45
454	Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers. Journal of Alzheimer's Disease, 2016, 50, 261-270.	2.6	14
455	Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2016, 49, 927-943.	2.6	41
456	Stability of Progranulin Under Pre-Analytical Conditions in Serum and Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2016, 53, 107-116.	2.6	5
457	Slowing of Hippocampal Activity Correlates with Cognitive Decline in Early Onset Alzheimer's Disease. An MEG Study with Virtual Electrodes. Frontiers in Human Neuroscience, 2016, 10, 238.	2.0	75
458	Application of Machine Learning to Arterial Spin Labeling in Mild Cognitive Impairment and Alzheimer Disease. Radiology, 2016, 281, 865-875.	7.3	58
459	A profile of The Clinical Course of Cognition and Comorbidity in Mild Cognitive Impairment and Dementia Study (The 4C study): two complementary longitudinal, clinical cohorts in the Netherlands. BMC Neurology, 2016, 16, 242.	1.8	17
460	Heterogeneous Language Profiles in Patients with Primary Progressive Aphasia due to Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 51, 581-590.	2.6	35
461	A Longitudinal Study on Resting State Functional Connectivity in Behavioral Variant Frontotemporal Dementia and Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 55, 521-537.	2.6	48
462	P1-297: The Diagnostic Value of Amyloid Pet in an Unselected Cohort of Memory Clinic Patients. , 2016, 12, P534-P535.		0
463	White Matter Hyperintensities Potentiate Hippocampal Volume Reduction in Non-Demented Older Individuals with Abnormal Amyloid- $\beta$ . Journal of Alzheimer's Disease, 2016, 55, 333-342.	2.6	16
464	Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 5, 43-52.	2.4	42
465	IC-03-02: Grey Matter Connectivity is Associated with Clinical Progression in Non-Demented, Amyloid Positive Patients. , 2016, 12, P9-P10.		0
466	P2-221: Cerebral Blood Flow Measured with Phase-Contrast MRI in AD, MCI and Controls. Alzheimer's and Dementia, 2016, 12, P706.	0.8	0
467	IC-P196: Quantification of TAU Load Using [ <sup>18</sup> F]AV-1451 and PET. Alzheimer's and Dementia, 2016, 12, P141.	0.8	0
468	P4-179: MEG Cross-Frequency Analysis in Patients With Alzheimer's Disease. , 2016, 12, P1087-P1088.		5

#	ARTICLE	IF	CITATIONS
469	P3-08-01: Grey Matter Connectivity is Associated with Time to Clinical Progression in Mild Cognitive Impairment, Independent of Amyloid Status. Alzheimer's and Dementia, 2016, 12, P303.	0.8	0
470	P1-178: Impact of Co-Morbid Amyloid Pathology on Clinical Phenotype of Patients with Vascular Cognitive Disorders. Alzheimer's and Dementia, 2016, 12, P472.	0.8	0
471	IC-03-05: EEG Directed Connectivity from Posterior Brain Regions is Decreased in Dementia with Lewy Bodies: A Comparison with Alzheimer's Disease And Controls. , 2016, 12, P12-P12.		0
472	P1-284: Grey Matter Connectivity is Associated With Clinical Progression in Non-Demented, Amyloid Positive Patients. Alzheimer's and Dementia, 2016, 12, P528.	0.8	0
473	P1-327: Cross-Sectional Modeling of Regional Perfusion and Gray Matter Volume in Alzheimer's Disease. , 2016, 12, P552-P553.		0
474	IC-P-097: A Novel Neuroimaging Approach to Capture Cognitive Reserve. Alzheimer's and Dementia, 2016, 12, P74.	0.8	0
475	IC-P-103: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Non-Demented Stages of Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P78.	0.8	0
476	IC-P-106: Cross-Sectional Modeling of Regional Perfusion and Gray Matter Volume in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P80.	0.8	0
477	IC-P-108: Cerebral Blood Flow Measured With Phase-Contrast MRI in AD, MCI and Controls. Alzheimer's and Dementia, 2016, 12, P82.	0.8	0
478	P2-348: Impact of Non-Pharmacologic Interventions on Cognitive, Behavioral, and Emotional Functioning in Older Adults with Subjective Cognitive Decline: A Systematic Review of Controlled Trials. , 2016, 12, P777-P777.		0
479	P2-282: EEG-Directed Connectivity from Posterior Brain Regions is Decreased in Dementia with Lewy Bodies: A Comparison with Alzheimer's Disease and Controls. Alzheimer's and Dementia, 2016, 12, P738.	0.8	0
480	IC-P-147: Atrophy Patterns Predicting Cognitive Decline in Non-Demented Subjects are Independent of Amyloid Pathology. Alzheimer's and Dementia, 2016, 12, P109.	0.8	0
481	P3-144: Cognitive Subtypes Identified Using Nonnegative Matrix Factorisation in Four Large Alzheimer's Disease Dementia Cohorts. Alzheimer's and Dementia, 2016, 12, P873.	0.8	0
482	IC-P-153: Thinner Cortical Thickness in Patients With Subjective Cognitive Decline is Related to Poor Memory Performance and Faster Decline of Executive Function. , 2016, 12, P113-P114.		1
483	P4-112: Amyloid Levels in the Normal Range are Predictive for Incident Dementia in Non-Demented Elderly. Alzheimer's and Dementia, 2016, 12, P1055.	0.8	0
484	P4-153: Subjective Cognitive Decline and Progression to Dementia Due to AD and Non-AD in Memory Clinic and Community-Based Cohorts. Alzheimer's and Dementia, 2016, 12, P1073.	0.8	1
485	P4-191: A Novel Neuroimaging Approach to Capture Cognitive Reserve. Alzheimer's and Dementia, 2016, 12, P1095.	0.8	0
486	P4-215: Quantification of Tau Load Using [ <sup>18</sup> F]AV-1451 and Pet. Alzheimer's and Dementia, 2016, 12, P1109.	0.8	0

#	ARTICLE	IF	CITATIONS
487	P4â€224: Alzheimerâ€™s Disease Patients With Osas History Have Higher CSF Tau Levels. Alzheimer's and Dementia, 2016, 12, P1115.	0.8	3
488	P4â€240: Deciding About Diagnostic Testing for Alzheimerâ€™s Disease: Patientsâ€™ Views and Experiences. Alzheimer's and Dementia, 2016, 12, P1122.	0.8	0
489	O1-01-01: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Non-Demented Stages of Alzheimerâ€™s Disease. , 2016, 12, P169-P170.		0
490	O1â€05â€02: Effects of Up to 14 Years of Biobank Storage of CSF Biomarkers AB42, TTAU, and PTAU. Alzheimer's and Dementia, 2016, 12, P183.	0.8	0
491	O4â€02â€04: Atrophy Patterns Predicting Cognitive Decline in Nonâ€Demented Subjects are Independent of Amyloid Pathology. Alzheimer's and Dementia, 2016, 12, P335.	0.8	0
492	O4-09-04: Towards Data-Driven Medicine in Differential Diagnostics of Neurodegenerative Diseases. , 2016, 12, P355-P355.		0
493	P1â€174: Costâ€Efficient Differential Diagnostics of Neurodegenerative Diseases Using A Stratified Approach. Alzheimer's and Dementia, 2016, 12, P469.	0.8	0
494	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 862-871.	0.8	93
495	Combinations of Service Use Types of People With Early Cognitive Disorders. Journal of the American Medical Directors Association, 2016, 17, 620-625.	2.5	7
496	Differential diagnosis of neurodegenerative diseases using structural MRI data. NeuroImage: Clinical, 2016, 11, 435-449.	2.7	137
497	Design of the NLâ€ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 233-240.	3.7	4
498	Cerebrospinal Fluid Alzheimerâ€™s Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. Journal of Alzheimer's Disease, 2016, 54, 287-295.	2.6	77
499	Malnutrition and Risk of Structural Brain Changes Seen on Magnetic Resonance Imaging in Older Adults. Journal of the American Geriatrics Society, 2016, 64, 2457-2463.	2.6	31
500	Pseudo-healthy Image Synthesis for White Matter Lesion Segmentation. Lecture Notes in Computer Science, 2016, , 87-96.	1.3	19
501	Clinical heterogeneity in familial Alzheimerâ€™s disease. Lancet Neurology, The, 2016, 15, 1296-1298.	10.2	21
502	ICâ€Pâ€011: The Diagnostic Value of Amyloid Pet in an Unselected Cohort of Memory Clinic Patients. Alzheimer's and Dementia, 2016, 12, P19.	0.8	0
503	P1-418: Cliniciansâ€™ Views and Attitudes on Shared Decision Making in Diagnostic Testing for Alzheimerâ€™s Disease. , 2016, 12, P595-P595.		0
504	P2â€335: Prevalence of Preclinical Alzheimer's Disease in Patients with Subjective Cognitive Decline: Comparison of Three European Memory Clinic Samples. Alzheimer's and Dementia, 2016, 12, P770.	0.8	0

#	ARTICLE	IF	CITATIONS
505	P2â€³42: Thinner Cortical Thickness in Patients with Subjective Cognitive Decline is Related to Poor Memory Performance and Faster Decline of Executive Function. <i>Alzheimer's and Dementia</i> , 2016, 12, P774.	0.8	0
506	O5-07-02: Personalized Risk Estimates for Mci Patients: Taking Biomarkers Into the Clinic. , 2016, 12, P393-P393.		1
507	ABCA7 p.G215S as potential protective factor for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 46, 235.e1-235.e9.	3.1	37
508	Differences in structural covariance brain networks between behavioral variant frontotemporal dementia and Alzheimer's disease. <i>Human Brain Mapping</i> , 2016, 37, 978-988.	3.6	48
509	Cortical phase changes measured using 7â€¢ MRI in subjects with subjective cognitive impairment, and their association with cognitive function. <i>NMR in Biomedicine</i> , 2016, 29, 1289-1294.	2.8	12
510	Suspected non-Alzheimer disease pathophysiology â€” concept and controversy. <i>Nature Reviews Neurology</i> , 2016, 12, 117-124.	10.1	230
511	Impact of Imaging and Cerebrospinal Fluid Biomarkers on Behavioral Variant Frontotemporal Dementia Diagnosis within a Late-Onset Frontal Lobe Syndrome Cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2016, 41, 16-26.	1.5	12
512	The effect of physical activity on cognitive function in patients with dementia: A meta-analysis of randomized control trials. <i>Ageing Research Reviews</i> , 2016, 25, 13-23.	10.9	455
513	Alzheimer Disease and Behavioral Variant Frontotemporal Dementia: Automatic Classification Based on Cortical Atrophy for Single-Subject Diagnosis. <i>Radiology</i> , 2016, 279, 838-848.	7.3	79
514	Cerebral perfusion in the predementia stages of Alzheimerâ€™s disease. <i>European Radiology</i> , 2016, 26, 506-514.	4.5	99
515	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. <i>Neurobiology of Aging</i> , 2016, 38, 214.e7-214.e10.	3.1	78
516	Different patterns of cortical gray matter loss over time in behavioral variant frontotemporal dementia and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 38, 21-31.	3.1	40
517	EEG-directed connectivity from posterior brain regions is decreased in dementia with Lewy bodies: a comparison with Alzheimer's disease and controls. <i>Neurobiology of Aging</i> , 2016, 41, 122-129.	3.1	52
518	Alzheimer's disease risk variants modulate endophenotypes in mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2016, 12, 872-881.	0.8	50
519	Gray matter network disruptions and amyloid beta in cognitively normal adults. <i>Neurobiology of Aging</i> , 2016, 37, 154-160.	3.1	51
520	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. <i>Alzheimer's and Dementia</i> , 2016, 12, 154-163.	0.8	179
521	Relation between subcortical grey matter atrophy and conversion from mild cognitive impairment to Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 425-432.	1.9	88
522	The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 235-243.	1.9	89

#	ARTICLE	IF	CITATIONS
523	A Semi-supervised Large Margin Algorithm for White Matter Hyperintensity Segmentation. Lecture Notes in Computer Science, 2016, , 104-112.	1.3	2
524	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. Brain, 2016, 139, 2528-2539.	7.6	58
525	Differential Dementia Diagnosis on Incomplete Data with Latent Trees. Lecture Notes in Computer Science, 2016, , 44-52.	1.3	1
526	P3-158: Grey matter network disruptions are related to amyloid beta in cognitively healthy elderly. , 2015, 11, P689-P689.		0
527	P1-174: Diagnostic impact of [18 F]flutemetamol amyloid imaging in young onset dementia. , 2015, 11, P411-P412.		0
528	P3-072: Are relations between ApoE genotype and ad-related pathology in nondemented elderly mediated by CSF apolipoproteins?. , 2015, 11, P644-P644.		0
529	O4-05-04: A four-center study on the effect of polygenic risk score on cerebrospinal fluid markers and memory decline in mild cognitive impairment patients. , 2015, 11, P279-P279.		0
530	Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 505-512.	2.4	81
531	IC-P-124: Classification of resting-state cerebral perfusion maps from patients with Alzheimer's disease and patients with frontotemporal dementia. , 2015, 11, P85-P85.		0
532	P1-093: Dementia and rapid mortality: Who's at risk?. , 2015, 11, P374-P374.		0
533	P2-298: Altered plasma and CSF levels of nutrients that enhance neuronal phospholipid synthesis in Alzheimer's disease: A retrospective cohort study. , 2015, 11, P606-P607.		0
534	Differential Expression of microRNA in Cerebrospinal Fluid as a Potential Novel Biomarker for Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 243-252.	2.6	35
535	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. Journal of Alzheimer's Disease, 2015, 48, S63-S86.	2.6	317
536	Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds. Journal of Alzheimer's Disease, 2015, 48, 711-720.	2.6	71
537	Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 46, 1103-1110.	2.6	55
538	Serum Leptin is not Altered nor Related to Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 809-813.	2.6	42
539	More Atrophy of Deep Gray Matter Structures in Frontotemporal Dementia Compared to Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 635-647.	2.6	46
540	Hypertensive Disorders of Pregnancy Appear Not to Be Associated with Alzheimer's Disease Later in Life. Dementia and Geriatric Cognitive Disorders Extra, 2015, 5, 375-385.	1.3	21

#	ARTICLE	IF	CITATIONS
541	P1-180: Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. , 2015, 11, P414-P414.		0
542	Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 46, 889-899.	2.6	11
543	IC-P-079: Lower cerebral blood flow is associated with cognitive decline in patients with Alzheimer's disease. , 2015, 11, P57-P57.		0
544	P4-089: Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to Alzheimer's disease. , 2015, 11, P806-P807.		1
545	IC-04-03: Grey matter network disruptions are related to amyloid-beta in cognitively healthy elderly. , 2015, 11, P11-P11.		0
546	IC-P-062: Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to Alzheimer's disease. , 2015, 11, P46-P47.		0
547	O3-09-02: An eeg study into functional connectivity and hubs in Alzheimer's disease: What's going on in the posterior regions?. , 2015, 11, P237-P238.		0
548	P1-166: A prospective validation study of the predictnd tool: A diagnostic decision support tool-rationale and design of the study. , 2015, 11, P408-P408.		0
549	O4-11-04: Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study. , 2015, 11, P297-P297.		1
550	Loss of <scp>EEG</scp><scp>N</scp>etwork <scp>E</scp>fficiency <scp>I</scp>s <scp>R</scp>elated to <scp>C</scp>ognitive <scp>I</scp>mpairment in <scp>D</scp>ementia <scp>W</scp>ith <scp>L</scp>ewy <scp>B</scp>odies. Movement Disorders, 2015, 30, 1785-1793.	3.9	65
551	Resting state functional connectivity differences between behavioral variant frontotemporal dementia and Alzheimer's disease. Frontiers in Human Neuroscience, 2015, 9, 474.	2.0	64
552	Trajectories of cognitive decline in different types of dementia. Psychological Medicine, 2015, 45, 1051-1059.	4.5	85
553	Alzheimer's disease first symptoms are age dependent: Evidence from the NACC dataset. Alzheimer's and Dementia, 2015, 11, 1349-1357.	0.8	93
554	Atrophy patterns in early clinical stages across distinct phenotypes of <scp>A</scp>lzheimer's disease. Human Brain Mapping, 2015, 36, 4421-4437.	3.6	196
555	O2-02-06: Slow gait speed and low grip strength are related to worse attention and mental speed in patients with subjective cognitive decline and mild cognitive impairment. , 2015, 11, P177-P177.		0
556	Joint assessment of white matter integrity, cortical and subcortical atrophy to distinguish AD from behavioral variant FTD: A two-center study. NeuroImage: Clinical, 2015, 9, 418-429.	2.7	38
557	F2-03-03: Characterization of the behavioral and dysexecutive variants of Alzheimer's disease. , 2015, 11, P168-P168.		0
558	IC-01-04: Diagnostic impact of [18 F]flutemetamol amyloid imaging in young-onset dementia. , 2015, 11, P3-P4.		2

#	ARTICLE	IF	CITATIONS
559	P3-142: Alzheimer's biomarkers in daily practice (ABIDE): Study design. , 2015, 11, P679-P680.		0
560	IC-P-089: Vascular and amyloid pathologies in memory clinic patients: Synergetic or independent?. , 2015, 11, P62-P62.		0
561	P4-100: Vascular and amyloid pathologies in memory clinic patients: Synergetic or independent?. , 2015, 11, P814-P814.		0
562	O1-07-02: Alzheimer's disease core biomarkers and prediction of dementia in MCI: The effect of age at onset. , 2015, 11, P140-P142.		0
563	F2-03-02: Early onset APOE-É4-negative Alzheimer's disease patients show faster cognitive decline on non-memory domains. , 2015, 11, P168-P168.		1
564	F2-03-04: Genetic risk factors for posterior cortical atrophy. , 2015, 11, P168-P169.		2
565	O3-14-02: Assessing underlying Alzheimer's disease pathology in MCI patients from the amsterdam dementia cohort by use of the predictad software tool. , 2015, 11, P254-P255.		0
566	O3-14-04: The relation between eeg spectral analysis and clinical progression in non-demented, amyloid-positive subjects. , 2015, 11, P255-P256.		1
567	F4-02-02: The influence of severity of total comorbidity on cognitive decline and conversion to dementia in memory clinic visitors. , 2015, 11, P260-P261.		0
568	O5-02-03: Reduced cortical thickness in patients with subjective cognitive decline is related to clinical progression. , 2015, 11, P317-P317.		0
569	O5-05-03: Neurogranin, a CSF biomarker for synaptic loss, predicts decline to dementia due to Alzheimer's disease. , 2015, 11, P326-P326.		0
570	The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 1605.e13-1605.e20.	3.1	27
571	Standardized evaluation of algorithms for computer-aided diagnosis of dementia based on structural MRI: The CADDementia challenge. NeuroImage, 2015, 111, 562-579.	4.2	266
572	Diagnostic impact of CSF biomarkers for Alzheimer's disease inÂ tertiary memory clinic. Alzheimer's and Dementia, 2015, 11, 523-532.	0.8	59
573	Prevalence and prognosis of Alzheimerâ€™s disease at the mild cognitive impairment stage. Brain, 2015, 138, 1327-1338.	7.6	284
574	Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1180-1190.	0.8	254
575	Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. Neurobiology of Aging, 2015, 36, 2340-2347.	3.1	49
576	Alzheimerâ€™s disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain, 2015, 138, 2701-2715.	7.6	109

#	ARTICLE	IF	CITATIONS
577	The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. <i>Brain</i> , 2015, 138, 2732-2749.	7.6	397
578	Cerebral perfusion and glucose metabolism in Alzheimer's disease and frontotemporal dementia: two sides of the same coin?. <i>European Radiology</i> , 2015, 25, 3050-3059.	4.5	80
579	The metabolic syndrome in a memory clinic population: Relation with clinical profile and prognosis. <i>Journal of the Neurological Sciences</i> , 2015, 351, 18-23.	0.6	19
580	Early onset APOE E4-negative Alzheimer's disease patients show faster cognitive decline on non-memory domains. <i>European Neuropsychopharmacology</i> , 2015, 25, 1010-1017.	0.7	43
581	Angiotensin-Converting Enzyme in Cerebrospinal Fluid and Risk of Brain Atrophy. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 153-162.	2.6	18
582	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	7.4	1,166
583	Prevalence of Amyloid PET Positivity in Dementia Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1939.	7.4	501
584	Mild cognitive impairment with suspected nonamyloid pathology (SNAP). <i>Neurology</i> , 2015, 84, 508-515.	1.1	122
585	The Rest-Activity Rhythm and Physical Activity in Early-Onset Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 45-49.	1.3	36
586	Microbleeds, Mortality, and Stroke in Alzheimer Disease. <i>JAMA Neurology</i> , 2015, 72, 539.	9.0	48
587	PLD3 variants in population studies. <i>Nature</i> , 2015, 520, E2-E3.	27.8	49
588	Standard biobanking conditions prevent evaporation of body fluid samples. <i>Clinica Chimica Acta</i> , 2015, 442, 141-145.	1.1	11
589	Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 59.	6.2	101
590	Declining functional connectivity and changing hub locations in Alzheimer's disease: an EEG study. <i>BMC Neurology</i> , 2015, 15, 145.	1.8	133
591	Identifying bvFTD Within the Wide Spectrum of Late Onset Frontal Lobe Syndrome: A Clinical Approach. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 1056-1066.	1.2	26
592	White Matter Hyperintensities Relate to Clinical Progression in Subjective Cognitive Decline. <i>Stroke</i> , 2015, 46, 2661-2664.	2.0	73
593	Prognostic Factors for Cognitive Decline After Intracerebral Hemorrhage. <i>Stroke</i> , 2015, 46, 2773-2778.	2.0	61
594	Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. <i>JAMA Neurology</i> , 2015, 72, 1275.	9.0	183

#	ARTICLE	IF	CITATIONS
595	7T T2*-weighted magnetic resonance imaging reveals cortical phase differences between early- and late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 20-26.	3.1	43
596	Disturbed phase relations in white matter hyperintensity based vascular dementia: An EEG directed connectivity study. <i>Clinical Neurophysiology</i> , 2015, 126, 497-504.	1.5	20
597	Widespread Disruption of Functional Brain Organization in Early-Onset Alzheimer's Disease. <i>PLoS ONE</i> , 2014, 9, e102995.	2.5	56
598	SUCLG2 identified as both a determinant of CSF A $\beta$ 1-42 levels and an attenuator of cognitive decline in Alzheimer's disease. <i>Human Molecular Genetics</i> , 2014, 23, 6644-6658.	2.9	45
599	Single-Subject Gray Matter Graph Properties and Their Relationship with Cognitive Impairment in Early- and Late-Onset Alzheimer's Disease. <i>Brain Connectivity</i> , 2014, 4, 337-346.	1.7	69
600	Mutation frequency of PRKAR1B and the major familial dementia genes in a Dutch early onset dementia cohort. <i>Journal of Neurology</i> , 2014, 261, 2085-2092.	3.6	10
601	The Dutch Parelinoer Institute - Neurodegenerative diseases; methods, design and baseline results. <i>BMC Neurology</i> , 2014, 14, 254.	1.8	57
602	The Added Value of 18-Fluorodeoxyglucose-Positron Emission Tomography in the Diagnosis of the Behavioral Variant of Frontotemporal Dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2014, 29, 607-613.	1.9	36
603	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. <i>Human Molecular Genetics</i> , 2014, 23, 6139-6146.	2.9	178
604	Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. <i>Neurology</i> , 2014, 82, 1768-1775.	1.1	51
605	Prevalence of cortical superficial siderosis in a memory clinic population. <i>Neurology</i> , 2014, 82, 698-704.	1.1	71
606	PL-02-02: PREDICTING CLINICAL PROGRESSION IN SUBJECTIVE COGNITIVE DECLINE. , 2014, 10, P162-P163.		0
607	Increased Number of Microinfarcts in Alzheimer Disease at 7-T MR Imaging. <i>Radiology</i> , 2014, 270, 205-211.	7.3	72
608	Amyloid and its association with default network integrity in Alzheimer's disease. <i>Human Brain Mapping</i> , 2014, 35, 779-791.	3.6	37
609	Brain volume and white matter hyperintensities as determinants of cerebral blood flow in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 2665-2670.	3.1	28
610	O3-06-02: A RE-EVALUATION OF EARLY ALZHEIMER'S DISEASE BIOMARKERS ACCOUNTING FOR INACCURACY OF THE CLINICAL DIAGNOSIS. , 2014, 10, P219-P219.		0
611	Associations Between Cerebral Small-Vessel Disease and Alzheimer Disease Pathology as Measured by Cerebrospinal Fluid Biomarkers. <i>JAMA Neurology</i> , 2014, 71, 855.	9.0	140
612	Building a New Paradigm for the Early Recognition of Behavioral Variant Frontotemporal Dementia: Late Onset Frontal Lobe Syndrome Study. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 735-740.	1.2	30

#	ARTICLE	IF	CITATIONS
613	Quantitative regional validation of the visual rating scale for posterior cortical atrophy. <i>European Radiology</i> , 2014, 24, 397-404.	4.5	27
614	Validation of the automated method VIENA: An accurate, precise, and robust measure of ventricular enlargement. <i>Human Brain Mapping</i> , 2014, 35, 1101-1110.	3.6	32
615	The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1190-8.	6.4	7
616	Apraxia in Mild Cognitive Impairment and Alzheimer's Disease: Validity and Reliability of the Van Heugten Test for Apraxia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 38, 55-64.	1.5	33
617	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 844-852.	0.8	1,863
618	Neurological abnormalities predict disability: the LADIS (Leukoaraiosis And DISability) study. <i>Journal of Neurology</i> , 2014, 261, 1160-1169.	3.6	16
619	The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 27.	6.2	63
620	Altered distribution of the EphA4 kinase in hippocampal brain tissue of patients with Alzheimer's disease correlates with pathology. <i>Acta Neuropathologica Communications</i> , 2014, 2, 79.	5.2	25
621	The Heart-Brain Connection: A Multidisciplinary Approach Targeting a Missing Link in the Pathophysiology of Vascular Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2014, 42, S443-S451.	2.6	45
622	Brain network alterations in Alzheimer's disease measured by Eigenvector centrality in fMRI are related to cognition and CSF biomarkers. <i>Human Brain Mapping</i> , 2014, 35, 2383-2393.	3.6	108
623	Comparison of Simplified Parametric Methods for Visual Interpretation of <sup>11</sup> C-Pittsburgh Compound-B PET Images. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1305-1307.	5.0	24
624	Distinct perfusion patterns in Alzheimer's disease, frontotemporal dementia and dementia with Lewy bodies. <i>European Radiology</i> , 2014, 24, 2326-2333.	4.5	50
625	Regional atrophy is associated with impairment in distinct cognitive domains in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, S299-305.	0.8	31
626	The structure of the geriatric depressed brain and response to electroconvulsive therapy. <i>Psychiatry Research - Neuroimaging</i> , 2014, 222, 1-9.	1.8	25
627	The cerebrospinal fluid 'Alzheimer profile': Easily said, but what does it mean?. <i>Alzheimer's and Dementia</i> , 2014, 10, 713.	0.8	249
628	Dysglycemia, brain volume and vascular lesions on MRI in a memory clinic population. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 85-90.	2.3	17
629	Actigraphic Motor Activity in Mild Cognitive Impairment Patients Carrying Out Short Functional Activity Tasks: Comparison between Mild Cognitive Impairment with and without Depressive Symptoms. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 869-875.	2.6	17
630	Optimizing Patient Care and Research: The Amsterdam Dementia Cohort. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 313-327.	2.6	307

#	ARTICLE	IF	CITATIONS
631	Concordance Between Cerebrospinal Fluid Biomarkers and [11C]PIB PET in a Memory Clinic Cohort. Journal of Alzheimer's Disease, 2014, 41, 801-807.	2.6	109
632	The Influence of Co-Morbidity and Frailty on the Clinical Manifestation of Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 501-509.	2.6	34
633	P1-258: CORTICAL PHASE CHANGES AT 7T MRI IN SUBJECTIVE COGNITIVE IMPAIRMENT AND THEIR ASSOCIATION WITH COGNITIVE FUNCTION. , 2014, 10, P402-P402.		1
634	O2-13-05: APOLIPOPROTEIN A-1 IS ASSOCIATED WITH DECLINE IN PRECLINICAL AD. , 2014, 10, P195-P196.		0
635	O5-02-02: LOBAR MICROBLEEDS PREDICT STROKE IN PATIENTS WITH ALZHEIMER'S DISEASE: THE MISTRAL STUDY. , 2014, 10, P291-P292.		0
636	P1-135: DIRECTED ANTERIOR-TO-POSTERIOR COMMUNICATION IN THE BRAIN IS REVERSED IN DEMENTIA WITH LEWY BODIES AND IS RELATED TO ATTENTION DEFICITS. , 2014, 10, P349-P349.		1
637	O2-13-03: MILD COGNITIVE IMPAIRMENT WITH SUSPECTED NON AD PATHOLOGY (SNAP): PREDICTION OF PROGRESSION TO DEMENTIA. , 2014, 10, P194-P195.		0
638	P1-223: MORE ATROPHY OF DEEP GRAY MATTER STRUCTURES IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA COMPARED TO ALZHEIMER'S DISEASE. , 2014, 10, P385-P386.		0
639	IC-P-009: NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN. , 2014, 10, P11-P12.		0
640	IC-P-085: COMPARING ATROPHY PATTERNS IN EARLY CLINICAL STAGES ACROSS DISTINCT PHENOTYPES OF ALZHEIMER'S DISEASE. , 2014, 10, P48-P49.		0
641	O4-01-05: CLINICALLY DIAGNOSED PROBABLE AD CASES WITH A NEGATIVE AMYLOID PET SCAN: CLINICAL FINDINGS. , 2014, 10, P250-P250.		1
642	P1-015: PROTEIN KINASE ACTIVITY DECREASES WITH BRAAK STAGE IN HIPPOCAMPAL POSTMORTEM BRAIN TISSUE AS REVEALED BY USING A PEPTIDE-BASED MICROARRAY PLATFORM. , 2014, 10, P309-P309.		0
643	P1-385: RATIONALE AND DESIGN OF THE NL-ENIGMA STUDY, A DUTCH 24-WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF A NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER'S DISEASE. , 2014, 10, P455-P456.		0
644	O2-07-04: COGNITIVE SUBTYPES IN DEMENTIA DUE TO ALZHEIMER'S DISEASE IDENTIFIED BY LATENT CLASS ANALYSIS. , 2014, 10, P178-P179.		0
645	IC-P-077: LOBAR MICROBLEEDS PREDICT STROKE IN PATIENTS WITH ALZHEIMER'S DISEASE: THE MISTRAL STUDY. , 2014, 10, P43-P44.		0
646	O4-01-06: NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN. , 2014, 10, P250-P251.		0
647	IC-P-013: DIAGNOSTIC VALUE OF AMYLOID IMAGING IN EARLY ONSET DEMENTIA. , 2014, 10, P14-P14.		3
648	IC-P-076: WHITE MATTER HYPERINTENSITIES PREDICT MILD COGNITIVE IMPAIRMENT AND DEMENTIA IN PATIENTS WITH SUBJECTIVE COGNITIVE COMPLAINTS. , 2014, 10, P42-P43.		1

#	ARTICLE	IF	CITATIONS
649	O2-14-03: THE REST-ACTIVITY RHYTHM IS RELATED TO THE LEVEL OF PHYSICAL ACTIVITY IN EARLY-ONSET DEMENTIA. , 2014, 10, P197-P198.		0
650	IC-P-056: MORE ATROPHY OF DEEP GRAY MATTER STRUCTURES IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA COMPARED TO ALZHEIMER'S DISEASE. , 2014, 10, P31-P32.		0
651	IC-P-109: RATIONALE AND DESIGN OF THE NL-ENIGMA STUDY: A DUTCH 24-WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER DISEASE. , 2014, 10, P61-P61.		1
652	P1-134: LOSS OF NETWORK INTEGRATION IS RELATED TO COGNITIVE IMPAIRMENT IN DEMENTIA WITH LEWY BODIES. , 2014, 10, P349-P349.		0
653	P1-149: CSF VILIP-1 AND YKL-40, NOVEL CANDIDATE BIOMARKERS TO DIAGNOSE, PREDICT, AND MONITOR ALZHEIMER'S DISEASE. , 2014, 10, P355-P355.		0
654	P4-273: CEREBROSPINAL FLUID NEUROGRANIN AS A PROGNOSTIC MARKER IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE. , 2014, 10, P884-P884.		0
655	O1-02-04: 7T T2*-WEIGHTED MRI REVEALS CORTICAL PHASE DIFFERENCES BETWEEN EARLY- AND LATE-ONSET AD. , 2014, 10, P132-P133.		0
656	O4-01-01: DIAGNOSTIC VALUE OF AMYLOID IMAGING IN EARLY ONSET DEMENTIA. , 2014, 10, P248-P248.		1
657	P3-096: MAGNETOENCEPHALOGRAPHY IN DEMENTIA: THE STATE OF THE ART. , 2014, 10, P663-P663.		1
658	P1-174: CEREBROVASCULAR DISEASE IN LATE ONSET FRONTAL LOBE SYNDROME. , 2014, 10, P363-P363.		0
659	P1-415: STUDY PROTOCOL: THE EFFECT OF PHYSICAL EXERCISE ON CEREBRAL BLOOD FLOW AND COGNITION IN PATIENTS WITH MILD VASCULAR COGNITIVE IMPAIRMENT. , 2014, 10, P465-P466.		0
660	Cerebral white matter changes are associated with abnormalities on neurological examination in non-disabled elderly: the LADIS study. Journal of Neurology, 2013, 260, 1014-1021.	3.6	34
661	Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer's and Dementia, 2013, 9, 414-421.	0.8	159
662	Alzheimer's disease patients not carrying the apolipoprotein E $\epsilon$ 4 allele show more severe slowing of oscillatory brain activity. Neurobiology of Aging, 2013, 34, 2158-2163.	3.1	19
663	Microglial activation in Alzheimer's disease: an (R)-[11C]PK11195 positron emission tomography study. Neurobiology of Aging, 2013, 34, 128-136.	3.1	145
664	S1-02-02: Clinical and neuropsychological features as predictors from MCI to Alzheimer's-type dementia. , 2013, 9, P122-P122.		0
665	O3-05-01: Physical activity, independent functioning and emotional well-being in early-onset dementia. , 2013, 9, P526-P526.		0
666	Cognitive correlates of cerebrospinal fluid biomarkers in frontotemporal dementia. , 2013, 9, 269-275.		19

#	ARTICLE	IF	CITATIONS
667	Different patterns of gray matter atrophy in early- and late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2014-2022.	3.1	156
668	O1-09-01: Diagnostic impact of CSF biomarkers for Alzheimer's disease in a memory clinic setting. , 2013, 9, P144-P145.		0
669	Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2488-2494.	3.1	66
670	Cerebrospinal fluid A $\beta$ 242 is the best predictor of clinical progression in patients with subjective complaints. <i>Alzheimer's and Dementia</i> , 2013, 9, 481-487.	0.8	164
671	Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study. <i>Alzheimer's and Dementia</i> , 2013, 9, 276-283.	0.8	25
672	F5-01-02: CSF biomarkers and APOE genotype as predictors of clinical progression in patients with subjective complaints. , 2013, 9, P824-P824.		1
673	Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. <i>Neurology</i> , 2013, 80, 1124-1132.	1.1	110
674	Alzheimer's disease: connecting findings from graph theoretical studies of brain networks. <i>Neurobiology of Aging</i> , 2013, 34, 2023-2036.	3.1	355
675	A prediction model to calculate probability of Alzheimer's disease using cerebrospinal fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2013, 9, 262-268.	0.8	22
676	Cerebral Blood Flow Measured with 3D Pseudocontinuous Arterial Spin-labeling MR Imaging in Alzheimer Disease and Mild Cognitive Impairment: A Marker for Disease Severity. <i>Radiology</i> , 2013, 267, 221-230.	7.3	206
677	Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. <i>Neurology</i> , 2013, 80, 359-365.	1.1	99
678	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. <i>Neurology</i> , 2013, 80, 1048-1056.	1.1	161
679	Preclinical AD predicts decline in memory and executive functions in subjective complaints. <i>Neurology</i> , 2013, 81, 1409-1416.	1.1	122
680	Cerebral atrophy in elderly with subjective memory complaints. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 38, 358-364.	3.4	9
681	Associations between Magnetic Resonance Imaging Measures and Neuropsychological Impairment in Early and Late Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 169-178.	2.6	21
682	Predictors of Progression from Mild Cognitive Impairment to Dementia in the Placebo-Arm of a Clinical Trial Population. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 79-85.	2.6	21
683	Progression to dementia in memory clinic patients without dementia. <i>Neurology</i> , 2013, 81, 1342-1349.	1.1	21
684	Increase in Cerebrospinal Fluid F2-Isoprostanes is Related to Cognitive Decline in APOE $\epsilon$ 4 Carriers. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 563-570.	2.6	19

#	ARTICLE	IF	CITATIONS
685	Single-Subject Grey Matter Graphs in Alzheimer's Disease. PLoS ONE, 2013, 8, e58921.	2.5	107
686	Integrative EEG biomarkers predict progression to Alzheimer's disease at the MCI stage. Frontiers in Aging Neuroscience, 2013, 5, 58.	3.4	143
687	Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology, 2012, 79, 1809-1816.	1.1	129
688	Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology, 2012, 78, 47-54.	1.1	255
689	Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement. Brain, 2012, 135, 2115-2125.	7.6	109
690	Early Onset Alzheimer's Disease is Associated with a Distinct Neuropsychological Profile. Journal of Alzheimer's Disease, 2012, 30, 101-108.	2.6	156
691	Bloodâ€“brain barrier P-glycoprotein function in Alzheimer's disease. Brain, 2012, 135, 181-189.	7.6	252
692	White Matter Lesion Progression in LADIS. Stroke, 2012, 43, 2643-2647.	2.0	88
693	Reply: Cerebral microbleeds in familial Alzheimer's disease. Brain, 2012, 135, e202-e202.	7.6	0
694	Injury Markers but not Amyloid Markers are Associated with Rapid Progression from Mild Cognitive Impairment to Dementia in Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 29, 319-327.	2.6	73
695	Improving the Accuracy and Precision of Cognitive Testing in Mild Dementia. Journal of the International Neuropsychological Society, 2012, 18, 314-322.	1.8	15
696	Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology, 2012, 78, 468-476.	1.1	154
697	Microbleeds in vascular dementia: Clinical aspects. Experimental Gerontology, 2012, 47, 853-857.	2.8	47
698	No Evidence for Additional Bloodâ€“Brain Barrier P-Glycoprotein Dysfunction in Alzheimer's Disease Patients with Microbleeds. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 1468-1471.	4.3	18
699	S2â€“02â€“01: Understanding (endo)phenotypical heterogeneity: The role of age and APOE. Alzheimer's and Dementia, 2012, 8, P228.	0.8	0
700	O4â€“03â€“01: Differential impact of apolipoprotein E genotype on distributions of amyloid load and glucose metabolism in Alzheimer's disease. Alzheimer's and Dementia, 2012, 8, P618.	0.8	0
701	Decreased mRNA expression of CCL5 [RANTES] in Alzheimer's disease blood samples. Clinical Chemistry and Laboratory Medicine, 2012, 50, 61-5.	2.3	21
702	Microglial activation in healthy aging. Neurobiology of Aging, 2012, 33, 1067-1072.	3.1	125

#	ARTICLE	IF	CITATIONS
703	Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. <i>Neurobiology of Aging</i> , 2012, 33, 1591-1598.	3.1	52
704	Resting-state fMRI changes in Alzheimer's disease and mild cognitive impairment. <i>Neurobiology of Aging</i> , 2012, 33, 2018-2028.	3.1	337
705	Young Alzheimer patients show distinct regional changes of oscillatory brain dynamics. <i>Neurobiology of Aging</i> , 2012, 33, 1008.e25-1008.e31.	3.1	34
706	Microbleeds relate to altered amyloid-beta metabolism in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 1011.e1-1011.e9.	3.1	55
707	Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. <i>Neurobiology of Aging</i> , 2012, 33, 2272-2281.	3.1	75
708	Microbleeds do not affect rate of cognitive decline in Alzheimer disease. <i>Neurology</i> , 2012, 79, 763-769.	1.1	72
709	Episodic memory and the medial temporal lobe: not all it seems. Evidence from the temporal variants of frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 1145-1148.	1.9	24
710	Disturbed oscillatory brain dynamics in subcortical ischemic vascular dementia. <i>BMC Neuroscience</i> , 2012, 13, 85.	1.9	24
711	Study protocol: EXERcise and Cognition In Sedentary adults with Early-ONset dementia (EXERCISE-ON). <i>BMC Neurology</i> , 2012, 12, 75.	1.8	14
712	Disruption of Functional Brain Networks in Alzheimer's Disease: What Can We Learn from Graph Spectral Analysis of Resting-State Magnetoencephalography?. <i>Brain Connectivity</i> , 2012, 2, 45-55.	1.7	85
713	Disrupted modular brain dynamics reflect cognitive dysfunction in Alzheimer's disease. <i>NeuroImage</i> , 2012, 59, 3085-3093.	4.2	190
714	Clinical aspects of microbleeds in Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2012, 322, 56-58.	0.6	18
715	Relationship between progression of brain white matter changes and late-life depression: 3-year results from the LADIS study. <i>British Journal of Psychiatry</i> , 2012, 201, 40-45.	2.8	85
716	Brain atrophy accelerates cognitive decline in cerebral small vessel disease. <i>Neurology</i> , 2012, 78, 1785-1792.	1.1	125
717	Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 990-1000.	6.4	145
718	Brain microbleeds and Alzheimer's disease: innocent observation or key player?. <i>Brain</i> , 2011, 134, 335-344.	7.6	291
719	Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 126-135.	1.9	588
720	Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: A 3-year follow-up of the LADIS study cohort. <i>Journal of the Neurological Sciences</i> , 2011, 307, 100-105.	0.6	57

#	ARTICLE	IF	CITATIONS
721	Progression from MCI to AD: Predictive value of CSF A $\beta$ 242 is modified by APOE genotype. <i>Neurobiology of Aging</i> , 2011, 32, 1372-1378.	3.1	12
722	F1-01-01: Early-onset versus late-onset Alzheimer's disease: A role for APOE e4?. , 2011, 7, S89-S89.		0
723	Evaluation of Intrathecal Serum Amyloid P (SAP) and C-Reactive Protein (CRP) Synthesis in Alzheimer's Disease with the Use of Index Values. <i>Journal of Alzheimer's Disease</i> , 2011, 22, 1073-1079.	2.6	21
724	Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE $\epsilon$ 4 allele. <i>Lancet Neurology</i> , The, 2011, 10, 280-288.	10.2	273
725	Visual assessment of posterior atrophy development of a MRI rating scale. <i>European Radiology</i> , 2011, 21, 2618-2625.	4.5	299
726	Clinical Relevance of Improved Microbleed Detection by Susceptibility-Weighted Magnetic Resonance Imaging. <i>Stroke</i> , 2011, 42, 1894-1900.	2.0	124
727	Incident lacunes influence cognitive decline. <i>Neurology</i> , 2011, 76, 1872-1878.	1.1	183
728	EEG Abnormalities Are Associated with Different Cognitive Profiles in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 31, 1-6.	1.5	21
729	Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 353-366.	2.3	140
730	EEG abnormalities in early and late onset Alzheimer's disease: understanding heterogeneity. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 67-71.	1.9	42
731	Joint Effect of Hypertension and APOE Genotype on CSF Biomarkers for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 1083-1090.	2.6	30
732	Translational Research in Genomics of Alzheimer's Disease: A Review of Current Practice and Future Perspectives. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 967-980.	2.6	16
733	Glycemia and Levels of Cerebrospinal Fluid Amyloid and Tau in Patients Attending a Memory Clinic. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 1318-1321.	2.6	11
734	Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 491-497.	1.5	38
735	Clinical Characteristics of Patients With Frontotemporal Dementia With and Without Lobar Atrophy on MRI. <i>Alzheimer Disease and Associated Disorders</i> , 2010, 24, 242-247.	1.3	19
736	Neurological Signs in Relation to White Matter Hyperintensity Volumes in Memory Clinic Patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 301-308.	1.5	6
737	Amyloid- $\beta$ 2(1-42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease. <i>Clinical Chemistry</i> , 2010, 56, 248-253.	3.2	301
738	New Research Criteria for the Diagnosis of Alzheimer's Disease Applied in a Memory Clinic Population. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 30, 1-7.	1.5	48

#	ARTICLE	IF	CITATIONS
739	Incidence of cerebral microbleeds. <i>Neurology</i> , 2010, 74, 1954-1960.	1.1	115
740	Diffusion-Weighted Imaging and Cognition in the Leukoariosis and Disability in the Elderly Study. <i>Stroke</i> , 2010, 41, e402-8.	2.0	82
741	Behavioural and psychological symptoms in vascular dementia; differences between small- and large-vessel disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 547-551.	1.9	103
742	Additional Value of CSF Amyloid- $\beta$ 240 Levels in the Differentiation between FTLD and Control Subjects. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 445-452.	2.6	39
743	Neuropsychological Predictors of Dementia in a Three-Year Follow-Up Period: Data from the LADIS Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 325-334.	1.5	25
744	Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: A longitudinal study. <i>Neurobiology of Aging</i> , 2010, 31, 758-764.	3.1	90
745	Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [ $^{11}\text{C}$ ]PIB and [ $^{18}\text{F}$ ]FDDNP PET images. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 882-884.	1.9	56
746	Early-Versus Late-Onset Alzheimer's Disease: More than Age Alone. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 1401-1408.	2.6	359
747	BACE1 Activity in Cerebrospinal Fluid and Its Relation to Markers of AD Pathology. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 253-260.	2.6	75
748	CSF $\beta$ -Synuclein Does Not Discriminate Dementia with Lewy Bodies from Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 87-95.	2.6	87
749	Prevalence and Clinical Significance of Epileptiform EEG Discharges in a Large Memory Clinic Cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 432-437.	1.5	60
750	Structural neuroimaging. , 2009, , 58-69.		31
751	CSF Biomarkers in Alzheimer's Disease and Controls: Associations with APOE Genotype are Modified by Age. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 601-607.	2.6	45
752	Most rapid cognitive decline in APOE $\epsilon$ 4 negative Alzheimer's disease with early onset. <i>Psychological Medicine</i> , 2009, 39, 1907-1911.	4.5	101
753	Location of lacunar infarcts correlates with cognition in a sample of non-disabled subjects with age-related white-matter changes: the LADIS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 478-483.	1.9	102
754	Relationship of Cerebrospinal Fluid Markers to $^{11}\text{C}$ -PiB and $^{18}\text{F}$ -FDDNP Binding. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1464-1470.	5.0	162
755	Detection of Alzheimer Pathology In Vivo Using Both $^{11}\text{C}$ -PiB and $^{18}\text{F}$ -FDDNP PET. <i>Journal of Nuclear Medicine</i> , 2009, 50, 191-197.	5.0	119
756	Hippocampal volume loss and Alzheimer disease progression. <i>Nature Reviews Neurology</i> , 2009, 5, 361-362.	10.1	22

#	ARTICLE	IF	CITATIONS
757	Associations between Patterns of EEG Abnormalities and Diagnosis in a Large Memory Clinic Cohort. Dementia and Geriatric Cognitive Disorders, 2009, 27, 18-23.	1.5	56
758	Carotid and Basilar Artery Wall Shear Stress in Alzheimer's Disease and Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2009, 28, 220-224.	1.5	12
759	Diagnostic Imaging of Patients in a Memory Clinic: Comparison of MR Imaging and 64â€“Detector Row CT. Radiology, 2009, 253, 174-183.	7.3	121
760	MRI Biomarkers of Vascular Damage and Atrophy Predicting Mortality in a Memory Clinic Population. Stroke, 2009, 40, 492-498.	2.0	118
761	CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. Neurology, 2009, 72, 1056-1061.	1.1	96
762	A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Annals of Clinical Biochemistry, 2009, 46, 235-240.	1.6	157
763	CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology, 2009, 73, 1353-1358.	1.1	130
764	Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. Neurology, 2009, 73, 935-940.	1.1	70
765	Hippocampal atrophy rates in Alzheimer disease. Neurology, 2009, 72, 999-1007.	1.1	315
766	Differential association of [ <sup>11</sup> C]PIB and [ <sup>18</sup> F]FDDNP binding with cognitive impairment. Neurology, 2009, 73, 2079-2085.	1.1	45
767	Functional neural network analysis in frontotemporal dementia and Alzheimer's disease using EEG and graph theory. BMC Neuroscience, 2009, 10, 101.	1.9	317
768	Quantitation of brain tissue changes associated with white matter hyperintensities by diffusion-weighted and magnetization transfer imaging: The LADIS (leukoaraiosis and disability in the Tj ETQq0 00rgBT /Overlock 10		
769	Knowing the natural course of biomarkers in AD: Longitudinal MRI, CSF and PET data. Journal of Nutrition, Health and Aging, 2009, 13, 353-355.	3.3	6
770	Accelerating regional atrophy rates in the progression from normal aging to Alzheimer's disease. European Radiology, 2009, 19, 2826-2833.	4.5	88
771	Patients With Alzheimer Disease With Multiple Microbleeds. Stroke, 2009, 40, 3455-3460.	2.0	202
772	Progression of Mild Cognitive Impairment to Dementia. Stroke, 2009, 40, 1269-1274.	2.0	128
773	CSF biomarker levels in early and late onset Alzheimer's disease. Neurobiology of Aging, 2009, 30, 1895-1901.	3.1	121
774	Longitudinal Cognitive Decline in Subcortical Ischemic Vascular Disease â€“ The LADIS Study. Cerebrovascular Diseases, 2009, 27, 384-391.	1.7	167

#	ARTICLE	IF	CITATIONS
775	CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. JAMA - Journal of the American Medical Association, 2009, 302, 385.	7.4	1,009
776	Heterogeneity of White Matter Hyperintensities in Alzheimer's Disease: Post-Mortem Quantitative MRI and Neuropathology. Neuroradiology Journal, 2009, 22, 51-63.	1.2	0
777	Clinical Evaluation and Treatment of Cognitive Dysfunction and Dementia. , 2009, , 103-127.		0
778	Small vessel versus large vessel vascular dementia. Journal of Neurology, 2008, 255, 1644-1651.	3.6	55
779	Behavioural and psychological symptoms are not related to white matter hyperintensities and medial temporal lobe atrophy in Alzheimer's disease. International Journal of Geriatric Psychiatry, 2008, 23, 387-392.	2.7	34
780	Transcranial Doppler Blood Flow Assessment in Patients With Mild Heart Failure: Correlates With Neuroimaging and Cognitive Performance. Congestive Heart Failure, 2008, 14, 61-65.	2.0	41
781	Global dynamical analysis of the EEG in Alzheimer's disease: Frequency-specific changes of functional interactions. Clinical Neurophysiology, 2008, 119, 837-841.	1.5	91
782	Investigation of resting-state EEG functional connectivity in frontotemporal lobar degeneration. Clinical Neurophysiology, 2008, 119, 1732-1738.	1.5	46
783	EEG functional connectivity and ApoE genotype in Alzheimer's disease and controls. Clinical Neurophysiology, 2008, 119, 2727-2732.	1.5	26
784	Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Current Medical Research and Opinion, 2008, 24, 2561-2574.	1.9	124
785	CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. Neurobiology of Aging, 2008, 29, 669-675.	3.1	103
786	Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology. Brain, 2008, 131, 3286-3298.	7.6	246
787	Variability in longitudinal cerebrospinal fluid tau and phosphorylated tau measurements. Clinical Chemistry and Laboratory Medicine, 2008, 46, 1300-4.	2.3	16
788	Reliability and Sensitivity of Visual Scales versus Volumetry for Evaluating White Matter Hyperintensity Progression. Cerebrovascular Diseases, 2008, 25, 247-253.	1.7	79
789	Early-Onset Dementia Is Associated with Higher Mortality. Dementia and Geriatric Cognitive Disorders, 2008, 26, 147-152.	1.5	82
790	The use of EEG in the diagnosis of dementia with Lewy bodies. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 377-380.	1.9	72
791	Distribution of APOE Genotypes in a Memory Clinic Cohort. Dementia and Geriatric Cognitive Disorders, 2008, 25, 433-438.	1.5	35
792	Neurological Signs in Relation to Type of Cerebrovascular Disease in Vascular Dementia. Stroke, 2008, 39, 317-322.	2.0	80

#	ARTICLE	IF	CITATIONS
793	Progression of White Matter Hyperintensities and Incidence of New Lacunes Over a 3-Year Period. <i>Stroke</i> , 2008, 39, 1414-1420.	2.0	348
794	Serum Amyloid P Component as a Biomarker in Mild Cognitive Impairment and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 522-527.	1.5	27
795	Cerebral Blood Flow by Using Pulsed Arterial Spin-Labeling in Elderly Subjects with White Matter Hyperintensities. <i>American Journal of Neuroradiology</i> , 2008, 29, 1296-1301.	2.4	72
796	Whole-brain atrophy rate in Alzheimer disease. <i>Neurology</i> , 2008, 70, 1836-1841.	1.1	94
797	Whole-Brain Atrophy Rate and Cognitive Decline: Longitudinal MR Study of Memory Clinic Patients. <i>Radiology</i> , 2008, 248, 590-598.	7.3	133
798	On the Etiology of Incident Brain Lacunes. <i>Stroke</i> , 2008, 39, 3083-3085.	2.0	76
799	Brain magnetic resonance imaging abnormalities in patients with heart failure. <i>European Journal of Heart Failure</i> , 2007, 9, 1003-1009.	7.1	130
800	Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. <i>Neurology</i> , 2007, 69, 1491-1497.	1.1	77
801	The Contribution of Medial Temporal Lobe Atrophy and Vascular Pathology to Cognitive Impairment in Vascular Dementia. <i>Stroke</i> , 2007, 38, 3182-3185.	2.0	107
802	Magnetic Resonance Imaging Predictors of Cognition in Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2007, 64, 1023.	4.5	67
803	Lobar Distribution of Changes in Gray Matter and White Matter in Memory Clinic Patients: Detected Using Magnetization Transfer Imaging. <i>American Journal of Neuroradiology</i> , 2007, 28, 1938-1942.	2.4	20
804	Longitudinal changes of CSF biomarkers in memory clinic patients. <i>Neurology</i> , 2007, 69, 1006-1011.	1.1	114
805	Comparison of the Alzheimer's Disease Assessment Scale Cognitive Subscale and the Vascular Dementia Assessment Scale in Differentiating Elderly Individuals with Different Degrees of White Matter Changes. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 73-81.	1.5	45
806	Apolipoprotein E Genotype Influences Presence and Severity of Delusions and Aggressive Behavior in Alzheimer Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 42-46.	1.5	49
807	Neuroimaging and Correlates of Cognitive Function among Patients with Heart Failure. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 418-423.	1.5	91
808	The effect of APOE genotype on clinical phenotype in Alzheimer disease. <i>Neurology</i> , 2007, 68, 624-624.	1.1	6
809	Prevalence and severity of microbleeds in a memory clinic setting. <i>Neurology</i> , 2007, 68, 391-391.	1.1	3
810	Cognitive Impairment in Alzheimer's Disease Is Modified by APOE Genotype. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 98-103.	1.5	66

#	ARTICLE	IF	CITATIONS
811	CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2007, 28, 1070-1074.	3.1	160
812	Diabetes mellitus, hypertension and medial temporal lobe atrophy: the LADIS study. <i>Diabetic Medicine</i> , 2007, 24, 166-171.	2.3	88
813	ASSOCIATION BETWEEN VITAMIN B <sub>6</sub> AND WHITE MATTER HYPERINTENSITIES IN PATIENTS WITH ALZHEIMER'S DISEASE NOT MEDIATED BY HOMOCYSTEINE METABOLISM. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 956-958.	2.6	10
814	Profile of Cognitive Impairment in Chronic Heart Failure. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 1764-1770.	2.6	160
815	Shifting Paradigms in Dementia: Toward Stratification of Diagnosis and Treatment Using MRI. <i>Annals of the New York Academy of Sciences</i> , 2007, 1097, 215-224.	3.8	27
816	Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural MRI study. <i>Neuroradiology</i> , 2007, 49, 967-976.	2.2	251
817	White Matter Hyperintensities Rather Than Lacunar Infarcts Are Associated With Depressive Symptoms in Older People: The LADIS Study. <i>American Journal of Geriatric Psychiatry</i> , 2006, 14, 834-841.	1.2	141
818	Magnetization transfer imaging of gray and white matter in mild cognitive impairment and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2006, 27, 1757-1762.	3.1	28
819	Simple versus complex assessment of white matter hyperintensities in relation to physical performance and cognition: the LADIS study. <i>Journal of Neurology</i> , 2006, 253, 1189-1196.	3.6	109
820	Infratentorial Abnormalities in Vascular Dementia. <i>Stroke</i> , 2006, 37, 105-110.	2.0	31
821	Prevalence and severity of microbleeds in a memory clinic setting. <i>Neurology</i> , 2006, 66, 1356-1360.	1.1	270
822	Hippocampal atrophy in Alzheimer disease: Age matters. <i>Neurology</i> , 2006, 66, 236-238.	1.1	127
823	Usefulness of Longitudinal Measurements of $\beta$ -Amyloid $\beta$ 42 in Cerebrospinal Fluid of Patients with Various Cognitive and Neurologic Disorders. <i>Clinical Chemistry</i> , 2006, 52, 1604-1606.	3.2	16
824	The effect of <i>APOE</i> genotype on clinical phenotype in Alzheimer disease. <i>Neurology</i> , 2006, 67, 526-527.	1.1	85
825	Can lumbar puncture help to identify patients with incipient Alzheimer's disease?. <i>Nature Clinical Practice Neurology</i> , 2006, 2, 530-531.	2.5	3
826	Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 439-442.	1.9	165
827	Multiple Diagnostic Tests Are Needed to Assess Multiple Causes of Dementia. <i>Archives of Neurology</i> , 2006, 63, 144.	4.5	14
828	A 24-year follow-up of body mass index and cerebral atrophy. <i>Neurology</i> , 2005, 64, 1990-1991.	1.1	0

#	ARTICLE	IF	CITATIONS
829	MRI measures and progression of cognitive decline in nondemented elderly attending a memory clinic. International Journal of Geriatric Psychiatry, 2005, 20, 1060-1066.	2.7	33
830	Medial temporal lobe atrophy and white matter hyperintensities are associated with mild cognitive deficits in non-disabled elderly people: the LADIS study. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1497-1500.	1.9	96
831	NINDS AIREN neuroimaging criteria do not distinguish stroke patients with and without dementia. Neurology, 2005, 65, 1341-1341.	1.1	0
832	Epidemiology and risk factors of dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, v2-v7.	1.9	374
833	Late-Onset Dementia: Structural Brain Damage and Total Cerebral Blood Flow. Radiology, 2005, 236, 990-995.	7.3	49
834	Neuropsychological Correlates of MRI Measures in the Continuum of Cognitive Decline at Old Age. Dementia and Geriatric Cognitive Disorders, 2005, 20, 82-88.	1.5	27
835	Use of laboratory and imaging investigations in dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, v45-v52.	1.9	11
836	Small Vessel Disease and General Cognitive Function in Nondisabled Elderly. Stroke, 2005, 36, 2116-2120.	2.0	311
837	Interaction of medial temporal lobe atrophy and white matter hyperintensities in AD. Neurology, 2004, 62, 1862-1864.	1.1	75
838	Memory complaints in patients with normal cognition are associated with smaller hippocampal volumes. Journal of Neurology, 2004, 251, 671-5.	3.6	156
839	Volumetric MRI predicts rate of cognitive decline related to AD and cerebrovascular disease. Neurology, 2003, 60, 1558-1559.	1.1	6
840	Cognitive decline in AD and mild cognitive impairment is associated with global brain damage. Neurology, 2002, 59, 874-879.	1.1	62
841	Magnetization transfer imaging in normal aging, mild cognitive impairment, and Alzheimer's disease. Annals of Neurology, 2002, 52, 62-67.	5.3	127
842	Hippocampal volume and cognition in geriatric depression. Biological Psychiatry, 2001, 50, 68-69.	1.3	2
843	Dementia with Lewy bodies and AD are not associated with occipital lobe atrophy on MRI. Neurology, 2001, 57, 2117-2120.	1.1	91
844	Frontal lobe damage and thalamic volume changes. NeuroReport, 2000, 11, 3039-3041.	1.2	7
845	Cerebral microbleeds and Alzheimer's disease. , 0, , 117-124.		0
846	Interaction between cerebral small vessel disease and neurodegenerative changes. , 0, , 298-310.		0